



GREGORC VANESA, MD

Department of Oncology

Istituto di Candiolo Fondazione del
Piemonte per l'Oncologia IRCCS (IT)

Strada Provinciale 142 - Km 3.95
10060 Candiolo (TO) Italy

Personal information

Date of birth: 13.09.1972

Tel: 011 993 3111

Email: vanesa.gregorc@ircc.it

Medical Registry N°39190

Citizenship: Italian

WORK EXPERIENCE

Since 2021 to present

Affiliation: Istituto di Candiolo - IRCCS Fondazione del Piemonte per l'Oncologia (IT)

2021- to present Deputy Scientific Director

2021 - to present Director of Medical Area

2021 - to present Director of Medical Oncology Department

Since 2003 to 2021

Affiliation: IRCCS Ospedale San Raffaele, Milano (IT)

2021 -11/2021 Coordinator of Cancer Center Medical Area

2020- 11/2021 Director of the Strategic Diagnostic-Therapeutic Oncological Innovation Program

**2015- 2021 Director of Thoracic Oncology, Melanoma and Head and Neck Unit at
Medical Oncology Department**

**2003-2015 Staff Physician of Thoracic Oncology, Melanoma and Head and Neck Unit at
Medical Oncology Department**

EDUCATION

2001- present: ECM educational activity on regular basis, Good Clinical Practice courses on regular basis, Advance Life Support courses on regular basis

2003- Diploma: The Page and William Black Post Graduate School, The Mont Sinai School of Medicine, NY, USA

1998-2002: Specialist in Medical Oncology (Post graduate specialization) University of Perugia, Faculty of Medicine and Surgery-Hospital Santa Maria della Misericordia

2001- Certificate: 2nd Intensive Workshop for European Junior Clinical Oncologists Federation of European Cancer Societies (FECS), American Association for Cancer Research (AACR), American Society of Clinical Oncology (ASCO)

2001-Certificate: Workshop on clinical protocol development - "Methods in Clinical Cancer Research" Flims, Switzerland

1995-2001 Clinical and Translational Research activities

Hospital Santa Maria della Misericordia, Division of Medical Oncology, Perugia

Phase II-III clinical trials and translational research activities under supervision of Dr. Maurizio Tonato, MD at Division of Medical Oncology, Perugia

1999-First **GCP course**, ASL (local health trust) Ravenna (Italy)

May 1998- Medical License exam Milan (85/90), University of Perugia, Faculty of Medicine and Surgery Medical Association

24/10/1997- Medical Degree (110/110 cum laude), University of Perugia, Faculty of Medicine and Surgery

1993-1995 Laboratory activity: University of Udine, Department of Pathology, Experimental, and Clinical Medicine. General Pathology Laboratory experience under the supervision of Prof. Francesco Ambesi Impiombato

1991-1993 University of Zagreb, Croatia Faculty of Medicine and Surgery (first 2 years)

1991- High School Degree Classical Lyceum "Branko Semelic", Pola, Croazia 60/60

MANAGEMENT and ORGANISATIONAL LEADERSHIP

2023- to present

Member of the OECI (Organisation of European Cancer Institutes, <https://www.oeci.eu/>) Accreditation and Designation Board to certify Cancer Institutes worldwide. Focus on care (patients pathways, multidisciplinary), research, education, organization, quality and budget. Main activity: definition and review of standards, evaluation of comprehensive cancer centers and networks; EU grants activities (CCI4EU, CraNE).

2022-to present

Auditor OECI (Organisation of European Cancer Institutes) Accreditation and Designation Programme to evaluate Cancer Institutes

2021-to present

Director of Medical Oncology Department at Istituto di Candiolo - IRCCS Fondazione del Piemonte per l'Oncologia (IT): Coordination of a clinical team of 24 medical oncologists, hematologist and other resources (PHD/fellows/medical students or interns) in **Day Hospital** (46 beds/infusion chairs, about 130 patients/day) and **Inpatient Department** for solid tumors, hematological oncology and bone marrow transplant (30 beds of which 4 dedicated bone marrow transplant) by planning and organization of operational clinical activity on bimonthly schedule, supervision, coordination (personal and operational), monitoring of clinical and research activities in line with our budget.

2021 - to present

Director of Medical Area at Istituto di Candiolo - IRCCS Fondazione del Piemonte per l'Oncologia (IT): Supervision and coordination of Centro Accoglienza e Servizi (CAS) and Gruppo Interdisciplinare Cure (GIC) of which 15 are active at Istituto di Candiolo -IRCCS Fondazione del Piemonte per l'Oncologia (IT). The CAS is a reference structure for all the first visits in institute of the patient for assistance, support and counseling. The GIC provides a care plan through its interdisciplinary clinical approach at institutional level. Main activity: supervision of organization, procedures and clinical, research, educational and quality activity.

2021- to present

Deputy Scientific Director at Istituto di Candiolo - IRCCS Fondazione del Piemonte per l'Oncologia (IT). Promoting the integration of Institute's researchers and research activity in the regional, national and international networks as well as building and nurturing relationships with public and private entities, including commercial ones, in order to create opportunities for commissioned research collaborations. Supporting the Scientific Director in defining three-year plans for current research promotion, data collection on scientific production related to the research projects carried out by the Institute in line with the research budget. My main focus is also coordination and management of the Clinical Trial Center that manages every year about 200 clinical and translational profit and not profit studies including phase I studies with the support of staff with appropriate professional skills, e.g. research managers, data managers, statisticians, research nurses, etc. Main activities are: scouting, promoting, planning, organizing research activities, supervising, monitoring and reporting clinical research activity.

2016- to present

General Secretary Working of Lung Group Lung - Alleanza Contro il Cancro (Alliance Against Cancer: the excellence network of Italian Cancer Institutes-IRCCS) and Member of the working groups: Lung, Melanoma, Immunology and Genomics. I coordinate National Lung Cancer program of 23 IRCCS since 2017 leading a program to improve molecular diagnostics at national level.

2010 - to present

Ministry of Health activities:

- ❖ Recognition and confirmation of the National Scientific Institutes (IRCCS) : member of the ministerial commission for the appointment of scientific directors, member of the ministerial commission for the recognition and maintenance of scientific research and treatment institutions
- ❖ Definition of National Health Research Program 2013-2015
- ❖ Budget distribution for current and targeted research (3 M euro/y); 2010-2014

2020- 2021

Director of the Strategic Diagnostic-Therapeutic Oncological Innovation Program at IRCCS Ospedale San Raffaele, Milano: introduction of extensive molecular profiling by building of interdivisional process to improve and optimize molecular diagnostics (NGS, proteomics), building molecular tumor board, promote telemedicine, early phase studies and patients care with innovative therapies in solid tumors.

2019- 2021

Project leader for the Cancer Center Accreditation and Cancer Center Medical Area Coordinator at the IRCCS Ospedale San Raffaele, Milano: Management and coordination of the professional resources to build and certify San Raffaele Cancer Center.

2017 - 2021

Co-Project Leader for the ONCOHOME project, San Raffaele Hospital, Cremona Hospital, National Cancer Institute (Istituto Nazionale Tumori Milano): building of institutional process to deliver telemedicine in cancer care because of COVID Pandemia.

2015-2021

Director of Thoracic Oncology, Melanoma and Head and Neck at IRCCS Ospedale San Raffaele, Milano: Coordination of a clinical team of medical oncologists and other resources (PHD/ fellows/ medical students or interns); organization and management of first visits, management of oncological emergencies and coordination of hospitalizations in collaboration with the head of the Internal Medicine department, Surgery and other medical departments. Care of patients with solid tumors, mostly represented by breast cancer, tumors of the gastrointestinal tract, lung, melanoma, gynecological oncology, sarcoma and urogenital area. and urogenital area.

2008- 2021

Head of Clinical Research Group:

Phase I Trials, Translational Research and Thoracic Oncology at the Division of Molecular Oncology IRCCS Ospedale San Raffaele: coordination on research group and program

2003-2021

Project Manager for the planning and organization of the Thoracic Unit IRCCS Ospedale San Raffaele. Coordination of multidisciplinary team.

TEACHING ACTIVITY

2012- to present

- ❖ **Contract Professor at Faculty of Medicine and Surgery University Vita - Salute, San Raffaele, Milan IT (2012-2021)**
- ❖ **Professor on appointment at School of Specialization in Thoracic Surgery University Vita - Salute, San Raffaele, Milan IT (2015-to present)**
- ❖ **Involvement in several educational events as a presenter, chief or scientific director.**

RESEARCH ACTIVITY

2008-to present:

Management as principal Investigator of more than 100 national and international clinical trials and research projects

2008-2021:

Clinical Group Leader at the Molecular Oncology Research Division, IRCCS San Raffaele Hospital for translational research on pulmonary neoplasms for personalized drug treatments.

Milestones achieved:

- **Identification of a proteomic profile** capable of classifying patients with non-small cell lung cancer from a prognostic point of view should be mentioned. This algorithm is currently also applied to neoplasms of the cervico-facial area. The profile was first identified in a retrospective study and confirmed by an Italian multicenter prospective study, designed and coordinated by Dr. Vanesa Gregorc as principal investigator. The proteomic profile was included in the Clinical Practice Guidelines in Oncology (NCCN), version 3 of 2014, as a tool to guide the choice of second-line treatment of patients with non-small cell lung cancer.
- **Development of an anti-vascular drug (NGR-hTNF)**, created in the laboratory of Prof Corti in collaboration with the pharmaceutical company Molmed S.p.A (Milan, Italy). **NGR-hTNF** underwent a Phase I, Phase II in patients with mesothelioma and in combination with chemotherapy in those with non-small cell lung cancer and microcytoma, and a Phase III trial in association with I-line chemotherapy in patients with mesothelioma.

2015-present

ESMO Faculty Member for Chest and other Thoracic Tumors

Since 2016

General Secretary of the Working Group Lung, creator, principal investigator and coordinator of a multicenter study, involving 20 Italian Centers. This study aims to introduce the use of Next Generation Sequencing in routine clinical practice, to improve the performance of molecular diagnostics in Italian institutes offering better therapies to patients with lung cancer. **Satellite studies:** Liquid Biopsy, Radiomics, Big Data, Tumor Molecular Board, miRNA.

Since 1998

Clinical and translational research of solid tumors as Principal Investigator and Sub Investigator of spontaneous and sponsored Phase I, II, III clinical trials (conducted in patients with solid tumors in the neoadjuvant, adjuvant and metastatic setting)

1993- 1995 Laboratory research: isolation and maintenance of cell cultures at the laboratory of General Pathology, Experimental and Clinical Medicine of the Faculty of Medicine and Surgery, University of Udine, under the supervision of Prof Saverio Ambesi Impiombato of the Department of General Pathology.

2013-present: Principal Investigator and Sub-Investigator of several Clinical and Translational Studies:

Phase I Trials

- CA052-002 NSCLC/SCCHN/CRC/UC/RCC/PDAC/TNBC) A Phase 1/2 Study of BMS-986340 as Monotherapy and in Combination with Nivolumab or Docetaxel in Participants with Advanced Solid Tumors
- PETRANHA A Multi-arm, Open-label Phase I/IIa Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of AZD5305 in Combination with New Hormonal Agents in Patients with Metastatic Prostate Cancer

- GFH925X0201 KROCUS A Phase Ib/II, Multi-Center, Open-Label Study to Evaluate the Safety/Tolerability, Pharmacokinetics, and Efficacy of GFH925 in Combination with Cetuximab in Previously Untreated Advanced NSCLC Harboring KRAS G12C Mutation
- TIG-006 A Multicenter, Open-Label, Phase I/II Study of EOS884448 in combination with standard of care and/or investigational therapies in participants with advanced solid tumors
- IM043-006 A Phase 1, Open-label, Multicenter Study of BMS-986360/CC-90001 Alone and in Combination with Chemotherapy or Nivolumab in Advanced Solid Tumors
- ELVN-002-001 A Phase 1a/1b Study of ELVN-002 for the Treatment of Patients with HER2 Mutant Non-Small Cell Lung Cancer Including Other Solid Tumors with HER2 Genetic Alterations
- 1479-0001 An open label, Phase I dose escalation trial, with dose confirmation and expansion, of BI 1810631 as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations

Phase II, III Profit trials

- NGR002. A modified phase I study of NGR-hTNF in advanced solid tumors: definition of an optimal biological dose – Sub investigator
- SAT2-05-07. A phase II study comparing sequential satraplatin and erlotinib to single-agent erlotinib in patients > 70 years of age with unresectable stage 3 or 4 Non-Small Cell Lung Cancer as 1st line therapy – Sub investigator
- NGR003. A phase IB study of NGR-hTNF in combination with doxorubicin in patients affected by advanced or metastatic solid tumor – Sub investigator
- NGR006. Phase II with NGR-Htnf at three-week intervals in patients with colorectal cancer previously treated with therapeutic regimens based on Fluoropyrimidine, Oxaliplatin and Irinotecan – Sub investigator
- NGR007. Phase II study of NGR-Htnf administration at three-week intervals in patients with advanced or metastatic small cell lung cancer (SCLC) previously treated with no more than one regimen – Sub investigator
- A8501002. International, randomized, open-label, phase 3 trial of gemcitabine/cisplatin plus pf-3512676 versus gemcitabine/cisplatin alone as first-line treatment of patients with advanced non-small cell lung cancer – Sub investigator
- D4200C00057. A phase III, randomised, double-blind, multi-centre parallel-group study to assess the efficacy of ZD6474 (Zactima™) versus Erlotinib (Tarceva®) in patients with locally advanced or metastatic (stage IIIB – IV) non-small cell lung cancer (NSCLC) after failure of at least one prior cytotoxic chemotherapy – Sub investigator
- NGR004. A phase IB study of NGR-hTNF in combination with cisplatin in patients affected by advanced or metastatic solid tumors – Sub investigator
- NGR010. Phase II study of intravenous administration of NGR-hTNF at three-week intervals in patients with advanced or metastatic malignant pleural mesothelioma previously treated with no more than one systemic regimen – Sub investigator
- Bay 43-9006/12006 A Phase III Randomized, Double-blind, Placebo Controlled Trial Comparing the Efficacy of Gemcitabine, Cisplatin and Sorafenib to Gemcitabine, Cisplatin and Placebo in First-Line Treatment of Patients with Stage IIIB with effusion and Stage IV Non-Small Cell Lung Cancer (NSCLC) – Sub investigator

- A6181087. A multicenter, randomized, double-blind, controlled phase III, efficacy and safety study of Sunitinib (SU011248) in patients with advanced/metastatic non-small cell lung cancer treated with erlotinib - Sub investigator
- H3E-CR-S111. Pemetrexed with simplified folate and dexamethasone supplementation versus pemetrexed with standard supplementation as second-line chemotherapy for patients with non-small cell lung cancer - Sub investigator
- NGR014. Randomized phase II study of NGR-hTNF in combination with standard chemotherapy versus standard chemotherapy alone in previously untreated patients with advanced non-small cell lung cancer (NSCLC) - Sub investigator
- OSI 774-302. Studio di fase 3, multicentrico, randomizzato, in doppio cieco, controllato verso placebo sul farmaco Tarceva (erlotinib) contenente un unico principio, somministrato in seguito a resezione chirurgica completa, con o senza chemioterapia adiuvante, a pazienti affetti da carcinoma non a piccole cellule di stadio IB-IIIa con tumori EGFR-positivi - Sub investigator
- NGR015. Randomized double-blind phase III study of NGR-hTNF plus best Investigator's choice (BIC) versus placebo plus BIC in previously treated patients with advanced malignant pleural mesothelioma (MPM) - Sub investigator
- H3E-EW-S128. Phase II Study of Pemetrexed, Cisplatin as induction, followed by Pemetrexed, Cisplatin combined with Radiotherapy in patients with unresectable locally advanced stage III Non-Squamous, Non-Small Cell Lung Cancer - Principal Investigator
- BP22349. A randomized, multicenter, open-label phase Ib/II study of RO5083945 in combination with cisplatin and gemcitabine/pemetrexed versus cisplatin and gemcitabine/pemetrexed in patients with advanced or recurrent non small cell lung cancer who have not received prior chemotherapy - Principal Investigator
- E7389-701. An open-label, multicenter, randomized phase Ib/II study of Eribulin Mesylate administered in combination with pemetrexed versus pemetrexed alone as second line therapy in patients with stage IIIB or IV nonsquamous non-small cell lung cancer-- Principal Investigator
- E7389-G000-302 A randomized, open-label, multicenter, phase 3 study to compare the efficacy and safety of eribulin with treatment of physician's choice in subjects with advanced non small cell lung cancer - Principal Investigator
- A8081005. Phase II, open-label, single arm study of the efficacy and safety of PF-02341066 in patients with advanced non-small cell lung cancer (NSCLC) harboring a translocation or inversion involving the anaplastic lymphoma kinase (ALK) gene locus - Sub investigator
- A8081007. Phase III, randomized, open-label study of the efficacy and safety of PF-02341066 versus standard of care chemotherapy (pemetrexed or docetaxel) in patients with advanced non-small cell lung cancer (NSCLC) harboring a translocation or inversion involving the anaplastic lymphoma kinase (ALK) gene locus - Sub investigator
- AVE8062. A multinational, randomized, double blind, controlled phase II trial of ombrambulin with taxane and platinum combination administered every three weeks, in first line treatment of patients with locally or metastatic Non Small Cell Lung Cancer (NSCLC) - Sub investigator
- CL1-78454-004. Phase I dose-escalation study of oral administration of the Pan-Histone Deacetylase (HDAC) Inhibitor S 78454 in combination with standard hypofractionated radiotherapy in patients with advanced solid tumour - Principal Investigator
- 107240. Phase I / II study to evaluate the safety and immunogenicity of the immunotherapeutic product recMAGE-A3 + AS15 administered as adjuvant therapy, with

- or without adjuvant chemo- / radiotherapy, in patients with MAGE-A3 positive non-small cell lung cancer (stage IB, II or III)- Sub investigator
- NGR015. Randomized double-blind phase III study of NGR-hTNF plus best Investigator's choice (BIC) versus placebo plus BIC in previously treated patients with advanced malignant pleural mesothelioma (MPM) - Sub investigator
- EFC10259. A multinational, randomized, double-blind, controlled phase II trial of ombrabulin with platinum and taxane combination administered every three weeks, in first line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) - Principal Investigator
- 1199,82. A phase I/II study of continuous oral treatment with BIBF 1120 added to standard gemcitabine/cisplatin therapy in first line NSCLC patients with squamous cell histology- Sub investigator
- MK-0000-083-01 A Multicenter Phase Ib Trial to Measure [18F]- Fluorodeoxyglucose Uptake by Positron Emission Tomography in Stage IIIB and IV Non-Small Cell Lung Cancer Before and After Chemotherapy With Gemcitabine and Cisplatin or Carboplatin - Principal Investigator
- MK-0646-008-01 A Phase Ib, multicenter Trial to Evaluate Molecular Determinants of Response to Erlotinib and MK-0646 in Advanced Non-Small-Cell lung Cancer - Principal Investigator
- NP28673 An open-label, non-randomized, multicenter phase I/II trial of RO5424802 given orally to non-small cell lung cancer patients who have ALK mutation and failed crizotinib treatment - Sub Investigator - Sub Investigator
- 1200,55 An open label trial of afatinib in treatment-naive (1st line) or chemotherapy pre-treated patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR mutation(s) - Sub Investigator - Sub Investigator
- GO28753 POPLAR An open-label, multicenter, randomized , phase II/III study to investigate the efficacy and safety of MPDL3280A compared with docetaxel in patients with non-small cell lung cancer after platinum failure - Sub Investigator
- CLDK378A2301 A phase III multicenter, randomized study of oral LDK378 versus standard chemotherapy in previously untreated adult patients with ALK rearranged (ALK-positive), stage IIIB or IV, non-squamous cell lung cancer - Sub Investigator
- D1532C00079 A phase III, double-blind, randomised, placebo-controlled study to assess the efficacy and safety of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in combination with Docetaxel, in patients receiving second line treatment for KRAS mutation-positive locally advanced or metastatic non small cell lung cancer (stage IIIB-IV) (SELECT-1) - Sub Investigator
- CLDK378A2303 A phase III multicenter randomized open label study of oral LDK378 versus standard chemotherapy in adult patients with ALK positive advanced NSCLC who have been treated previously with chemotherapy platinum doublet and crizotinib - Sub Investigator
- CA209172 A single arm, open-label, multicenter clinical trial with Nivolumab (BMS-963558) for subjects with histologically confirmed stage III (unresectable) or stage IV melanoma progressing post prior treatment containing an anti-CTLA-4 monoclonal antibody
- BR26 Double-blind, placebo-controlled, randomized study of PF-804 in patients with stage IIIB / IV incurable non-small cell lung cancer after failure of standard therapy for advanced or metastatic disease - Sub Investigator

- BRIM8A phase III, randomized, double-blind, placebo-controlled study of Vemurafenib (RO5185426) adjuvant therapy in patients with surgically resected, cutaneous braf-mutant melanoma at high risk for recurrence
- E-3810-II-02 A single arm, open-label, phase II study to assess the efficacy of the dual VEGFR-FGFR tyrosine kinase inhibitor, lucitanib, given orally as a single agent to patients with FGRF1-driven lung cancer - Sub Investigator
- GO28915 OAK A phase III, open-label multicenter, randomized study to investigate the efficacy and safety of MPDL3280A (antiPD-L1 antibody) compared with docetaxel in patients with non small cell lung cancer after platinum failure - Sub Investigator
- EPIC Multicenter, randomized, phase III study comparing personalized I-line chemotherapy to standard chemotherapy in elderly patients with advanced / metastatic non-small cell lung cancer - Sub investigator
- AURA 2 D5160C00002 A phase II, open label, single-arm study to assess the safety and efficacy of AZD9291 in patients with locally advanced/metastatic non small cell lung cancer whose disease has progressed with previous Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and whose Tumours are Epidermal Growth Factor Receptor Mutation and T790M Mutation Positive (AURA2) - Sub Investigator
- NGR019 Randomized double-blind phase II study of NGR-hTNF versus placebo as maintenance treatment patients with advanced malignant pleural mesothelioma (MPM) - Sub Investigator
- AP26113-201 Randomized Phase 2 study of AP26113 in patients with ALK-positive non-small cell lung cancer (NSCLC) previously treated with crizotinib - Sub Investigator
- D4191C00004 ARCTIC A Phase III, Open label, Randomised, Multi-centre, International Study of MEDI4736, versus Standard of Care in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB-IV) Who Have Received at Least Two Prior Systemic Treatment Regimens Including One Platinum-based Chemotherapy Regimen and Do Not Have Known EGFR TK Activating Mutations or ALK Rearrangements (ARCTIC) - Sub Investigator
- D4191C00001 PACIFIC Phase III, Randomised, Double-blind, Placebo-controlled, Multi-centre, International Study of MEDI4736 as Sequential Therapy in Patients with Locally Advanced, Unresectable Non-Small Cell Lung Cancer (Stage III) Who Have Not Progressed Following Definitive, Platinum-based, Concurrent Chemoradiation Therapy (PACIFIC) - Sub Investigator
- D4194R00005 PACIFIC-R First real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy
- D9103C00001 - PACIFIC-4 A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Following Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients with unresected Stage I/II, lymph-node negative Non-small Cell Lung Cancer (PACIFIC-4/RTOG-3515)
- D9108C00001 COAST A phase 2, open-label, multicenter, randomized, multidrug platform study of Durvalumab alone or in combination with novel agents in subjects with locally advanced, unresectable, stage III non-small cell lung cancer
- AV-299-14-206 A phase 2, multicenter, randomized, double-blind study of ficlatuzumab plus erlotinib versus placebo plus erlotinib in subjects who have previously untreated metastatic, EGFR-mutated non-small cell lung cancer (NSCLC) and BDX004 positive label - Sub Investigator

- B7461001 Phase 1/2 study of PF-06463922 (an ALK/ROS1 tyrosine kinase inhibitor) in patients with advanced non-small cell lung cancer harboring specific molecular alterations - Sub Investigator
- BO40336 A phase III, open label, randomized study to evaluate the efficacy and safety of adjuvant Alectinib versus adjuvant platinum-based chemotherapy in patients with completely resected stage IB (tumors ≥ 4 cm) to stage IIIA anaplastic lymphoma kinase-positive non small cell lung cancer
- I4T-MC-JVCY A multicenter, randomized, double-blind study of Erlotinib in combination with ramucirumab or placebo in previously untreated patients with EGFR mutation-positive metastatic non-small cell lung cancer - Sub Investigator
- GO29431 A phase III, open-label randomized study of MPDL3280A (anti-PD-L1 antibody) compared with Cisplatin or Carboplatin + Pemetrexed for PD-L1 selected chemotherapy Naive patients with stage IV non-squamous non-small cell lung cancer - Sub Investigator
- GO29432 A phase III, open-label, randomized study of MPDL3280A (anti-PD-L1 antibody) compared with Gemcitabine + Cisplatin or Carboplatin for PD-L1-selected, chemotherapy naive patients with stage IV squamous non-small cell lung cancer - Sub Investigator
- D5164C0001 ADAURA A phase III, double-blind, randomized, placebo-controlled multicentre, study to assess the efficacy and safety of AZD9291 versus placebo in patients with Epidermal Growth Factor Receptor mutation positive stage IB-III A non-small cell lung carcinoma, following complete tumour resection with or without adjuvant chemotherapy - Sub Investigator
- CC-486-NSCLC-001 A phase 2 multicenter, randomized, placebo controlled, double blind study to assess the safety and efficacy of CC-486 (oral azacitidine) in combination with pembrolizumab versus pembrolizumab plus placebo in subjects with previously treated locally advanced and/or metastatic non-small cell lung cancer - Sub Investigator
- GO29527 phase III, open label, randomized study to investigate the efficacy and safety of MPDL3280A (Anti-PD-L1 Antibody) therapy compared with standard of care following adjuvant cisplatin-based chemotherapy in PDL-1 selected patients with completely resected Stage IB-III A Non-Small Cell Lung Cancer (NSCLC)
- D419AC00001 MYSTIC A phase III randomized, open-label, multi-center, global study of first-line MEDI4736 in combination with Tremelimumab and MEDI4736 monotherapy versus standard of care platinum-based chemotherapy in first line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) - Sub Investigator
- MO29750 Randomized, multicenter, phase III, open-label study of alectinib versus chemotherapy in anaplastic lymphoma kinase positive advanced non-small cell lung cancer patients previously treated with chemotherapy and crizotinib - Sub Investigator
- ML41118 A phase IIIb, single arm, multicenter study of Atezolizumab (Tecentriq) in combination with carboplatin plus etoposide to investigate safety and efficacy in patients with untreated extensive stage SCLC
- ARRAY 818-202 A Phase 2, Open-label Study of Encorafenib + Binimetinib in Patients with BRAFV600E-mutant Non-small Cell Lung Cancer
- 265-109 Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor - Sub Investigator
- TO-TAS-114-201 A randomized, open-label, multi-center, international phase 2 study of TAS-114 in combination with S-1 in patients with advanced or metastatic non-small cell lung cancer

- MO29872 A phase III, open-label, multicenter, randomized study to investigate the efficacy and safety of Atezolizumab compared with chemotherapy in patients with treatment-naïve advanced or recurrent (stage IIIB not amenable for multimodality treatment) or metastatic (stage IV) non-small cell lung cancer who are deemed unsuitable for platinum-containing therapy - Sub Investigator
- AP26113-301 A Phase 3 Multicenter Open-label Study of Brigatinib (AP26113) versus Crizotinib in Patients with ALK-positive advanced lung cancer - Sub Investigator
- MK3475-407 A randomized, double-blind, phase III study of Carboplatin-Paclitaxel/Nab-paclitaxel chemotherapy with or without Pembrolizumab (MK-3475) in first line metastatic squamous non-small cell lung cancer subjects - Sub Investigator
- MK3475-671 A phase III, randomized, placebo-controlled trial of platinum doublet chemotherapy +/- Pembrolizumab (MK3475) as neoadjuvant/adjuvant therapy for participants with resectable stage IIB[N1] or IIIA Non-Small Cell Lung Cancer (NSCLC) (KEYNOTE-671)
- CA018-001 A Phase 2, Fast Real -time Assessment of Combination Therapies in Immuno - Oncology Study in Subjects with Advanced Non - small Cell Lung Cancer (FRACTION-Lung) - Sub Investigator
- CINC280A2201 A phase II, multicenter, study of oral cMET inhibitor INC280 in adult patients with EGFR wild-type (wt), advanced nonsmall cell lung cancer (NSCLC) - Sub Investigator
- CACZ885T2301 A phase III multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of Canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v.8 II-IIIa and IIIB (T>5cm N2) completely resected (R0) non-small cell lung cancer (NSCLC)
- CACZ885U2301 A randomized, double blind, placebo-controlled, phase III study evaluating the efficacy and safety of pembrolizumab plus platinum-based chemotherapy with or without canakinumab as first line therapy for locally advanced or metastatic non-squamous and squamous non-small cell lung cancer (NSCLC) subjects (CANOPY-1)
- BRIGATINIB-3001 A phase 3 randomized open-label study of Brigatinib (Alunbrig) versus Alectinib (Alecensa) in advanced anaplastic lymphoma kinase-positive non-small cell lung cancer patients who have progressed on Crizotinib (Xalkori)
- B7461006 Phase 3, randomized, open-label study of efficacy and safety of lorlatinib monotherapy vs crizotinib monotherapy as 1st line treatment of patients with advanced ALK-positive NSCLC - Sub Investigator
- CA209-9LA A Study of Nivolumab plus Ipilimumab in Combination with Chemotherapy vs Chemotherapy alone as First Line Therapy in Stage IV Non-Small Cell Lung Cancer (NSCLC) - Sub Investigator
- MK3475-715 A Randomized Phase 3 Trial of the Combination of Pembrolizumab (MK-3475) Plus Epacadostat (INCB024360) Alone or with Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy in Treatment-naïve Patients with Metastatic Non-Small Cell Lung Cancer - Sub Investigator
- I3Y-MC-JPCE A Phase 2 Study of Abemaciclib in Combination with Pembrolizumab for Patients with Stage IV Non-Small Cell Lung Cancer or Hormone Receptor Positive, HER2 Negative Breast Cancer - Sub Investigator
- ONC-2007-003 A randomized phase II study of progression free survival comparing carboplatin (AUC5 infusion) plus alimta (500 mg/m² infusion) versus gemcitabine (1250 mg/m²) as first-line chemotherapy in elderly patients with locally advanced (stage IIIb) or metastatic (stage IV) Non Small Cell Lung Cancer (NSCLC) - Principal Investigator

- BRAF113928 A Phase II study of the selective BRAF kinase inhibitor GSK218436 in subjects with advanced non small cell lung cancer and BRAF mutations - Sub Investigator
- EMR200095006 Randomized, open-label, Phase Ib / II trial comparing Tepotinib (MSC2156119J) combined with Gefitinib versus chemotherapy as II-line treatment in subjects with locally advanced or metastatic non-small cell lung cancer (NSCLC) MET + mutation in EGFR and acquired resistance to previous EGFR tyrosine kinase inhibitor therapy (EGFR-TKi) - Sub investigator
- CPDR001C2101 Open-label multicentre phase Ib study, with PDR001 in association with chemotherapy with a platinum-containing brace in patients with metastatic lung cancer, not selected for the expression of PDL-1- Sub investigator
- C4221008 (2019-000417-37) Pfizer - AIOM- National Coordinator
- NIVACTOR Single-arm, open-label, multicentre, phase IIIb clinical study with Nivolumab in subjects with recurrent or metastatic head and neck squamous cell carcinoma refractory to platinum therapy (SCCHN)
- 20190924 "A Non-interventional Biomarker Study on the Molecular Evaluation of Archival Tumor Tissue in Subjects with Non-Small Cell Lung Cancer (NSCLC)" Principal Investigator
- D4194R00016 BE-PACIFIC Italian observational study on Patient management strategies in real-world Clinical practice For patients with locally advanced (stage III) NSCLC - Principal Investigator
- 20190009 A Phase 3 Multicenter, Randomized, Open Label, activecontrolled, Study of AMG 510 Versus Docetaxel for the Treatment of previously treated Locally Advanced and unresectable or Metastatic NSCLC Subjects with KRAS p.G12C Mutation - Principal Investigator
- APL-101-01 Phase 1/2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects with Non-Small Cell Lung Cancer with c-Met EXON 14 skip mutations and c-MET Dysregulation Advance Solid Tumors - Principal Investigator
- BLU-667-2303 A Randomized, Open-Label, Phase 3 Study of Pralsetinib versus Standard of Care for First Line Treatment of RET fusion-positive, Metastatic Non-Small Cell Lung Cancer
- AEGEAN D9106C00001 A phase III, double-blind, placebo-controlled, multi-center international study of neoadjuvant/adjvant durvalumab for the treatment of patients with resectable stage II and III non-small cell lung cancer (AEGEAN) Principal Investigator
- B7461027 Single-Arm Study of Lorlatinib in Participants with Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer (NSCLC) Whose Disease Progressed After One Prior Second-Generation ALK Tyrosine Kinase Inhibitor (TKI) Principal Investigator
- 209227 INDUCE-4 A randomized, double-blind, phase III study of GSK3359609 in combination with pembrolizumab and platinum-based chemotherapy versus placebo in combination with pembrolizumab plus platinum-based chemotherapy for first-line treatment of recurrent/metastatic head and neck squamous cell carcinoma - Principal Investigator
- CDBR436BIT02 pattern of response/progression to first line treatment with dabrafenib and trametinib in patients with unresectable or metastatic BRAF mutations positive cutaneous melanoma: the T-WIN study - Principal Investigator

- ARRAY818-201 A Phase 2, Open-Label, Multicenter Trial of Encorafenib + Binimetinib Evaluating a Standard-dose and a High-dose Regimen in Patients with BRAFV600-Mutant Melanoma Brain Metastasis – Principal Investigator
- A Phase 3 Randomized, Double-blind, Multicenter, Global Study of Monalizumab or Placebo in Combination With Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated With an Immune Checkpoint Inhibitor – Principal Investigator
- Single-Arm Study of Lorlatinib in Participants with Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer (NSCLC) Whose Disease Progressed After One Prior Second-Generation ALK Tyrosine Kinase Inhibitor (TKI) Principal Investigator
- A phase 3 study of Pembrolizumab (MK-3475) in combination with concurrent chemoradiation therapy followed by Pembrolizumab with or without Olaparip, compared to concurrent chemoradiation therapy followed by placebo in participants with newly diagnosed untreated Limited-Stage Small Cell Lung Cancer (LS-SCLC) Principal Investigator
- A Phase 3, Randomized, Double-Blind Placebo-Controlled, Multicenter Study Comparing Niraparib plus Pembrolizumab versus Placebo plus Pembrolizumab as Maintenance Therapy in Participants Whose Disease Has Remained Stable or Responded to First-Line Platinum-Based Chemotherapy with Pembrolizumab For Stage IIIb or IV Non-Small Cell Lung Cancer – Principal Investigator
- BOUQUET - WO42178 A phase II, open-label, multicenter, platform study evaluating the efficacy and safety of biomarker-driven therapies in patients with persistent or recurrent rare epithelial ovarian tumors.
- MK-3475-B21 A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination With Adjuvant Chemotherapy With or Without Radiotherapy for the Treatment of Newly Diagnosed High-Risk Endometrial Cancer After Surgery With Curative Intent
- Siendo A Randomized, Double-Blind, Phase 3 Trial Of Maintenance With Selinexor/ Placebo After Combination Chemotherapy For Patients With Advanced Or Recurrent Endometrial Cancer
- PASS Zejula Post-authorization safety study to evaluate the risks of myelodysplastic syndrome/acute myeloid leukemia and second primary malignancies in adult patients with platinum-sensitive, relapsed, high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer receiving maintenance treatment with ZEJULA® (niraparib)
- KRT-232-Phase 2/3 study of navtemadlin as maintenance therapy in subjects with advanced or relapsed endometrial cancer with TP53WT who have responded to chemotherapy
- PRIMA A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients with Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy
- ATHENA A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy
- MK-3475-A18 (Interventistico, Profit – Sponsor: MSD) A Randomized, Phase 3, Double-Blind Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-risk, Locally Advanced Cervical Cancer

- Destiny-Breast 05 A Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Study Of Trastuzumab Deruxtecan (T-DXd) versus Trastuzumab Emtansine (T-Dm1) in Subjects with High-Risk Her2-Positive Primary Breast Cancer who have Residual Invasive Disease in Breast or Axillary Lymph Nodes Following Neoadjuvant Therapy
- DESTINY-Breast 11: A Phase 3 Open-label Trial of Neoadjuvant Trastuzumab Deruxtecan (T-DXd) Monotherapy or T-DXd followed by THP Compared to ddAC-THP in Participants with High-risk HER2-positive Early-stage Breast Cancer.
- Zest-213831 A Randomized Phase 3 Double-Blinded Study Comparing the Efficacy and Safety of Niraparib to Placebo in Participants with Either Her2-Negative BRCA-Mutated or Triple-Negative Breast Cancer with Molecular Disease Based on Presence of Circulating Tumor Dna after Definitive Therapy
- TRIO033-NATALEE: A phase III, multicenter, randomized, open-label trial to evaluate efficacy and safety of ribociclib with endocrine therapy as an adjuvant treatment in patients with hormone receptor-positive, HER2-negative, early breast cancer
- B041843 - persevERA A phase III randomized, double-blind, placebo-controlled, multicenter study evaluating the efficacy and safety of GDC-9545 combined with palbociclib compared with letrozole combined with palbociclib in patients with estrogen receptor-positive, her2-negative locally advanced or metastatic breast cancer
- BioitalEE- CLEE011AIT01 A phase IIIb, open-label, local, multicenter study of the molecular features of postmenopausal women with hormone receptor-positive (HR+) HER2-negative advanced breast cancer on first-line treatment with ribociclib and letrozole
- ROSY-O D0817C00098 : A Master, Roll Over Study for Patients Who Have Completed a Previous Oncology Study and Are Judged by the Investigator to Clinically Benefit From Continued Treatment
- DESTINY 06 A Phase 3, Randomized, Multi-center, Open-label Study of trastuzumab Deruxtecan (T-DXd) Versus Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy in the Metastatic Setting
- TROPION BREST 01(profit) A Phase 3, Open-label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy in Participants With Inoperable or Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy
- Impassion 132 A Phase III, Randomised, Double-Blind, Placebo-Controlled, Multicentre Study of The Efficacy And Safety of Atezolizumab Plus Chemotherapy for Patients with Early Relapsing Recurrent (Inoperable Locally Advanced Or Metastatic) Triple-Negative Breast Cancer
- El1ssar An Open-Label, Phase IIIb, Single Arm, Multicenter Safety Study of Atezolizumab (Tecentriq) plus Nabpaclitaxel or Paclitaxel In The Treatment of Unresectable Locally Advanced Or Metastatic Triple-Negative Breast Cancer
- Katherine (Profit) A Randomized, Multicenter, Open-Label Phase III Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine versus Trastuzumab as Adjuvant Therapy for Patients with Her2-Positive Primary Breast Cancer who Have Residual Tumor Present Pathologically in the Breast or Axillary Lymphnodes Following Preoperative Therapy
- BURAN The BURAN Study of Buparlisib (AN2025) in Combination with Paclitaxel Compared to Paclitaxel Alone, in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

- TRILYNX A randomized, double-blind placebo-controlled, Phase 3 study of Debio 1143 in combination with platinum-based chemotherapy and standard fractionation intensity-modulated radiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck, suitable for definitive chemoradiotherapy
- INCAGN2385-203 A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS \geq 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck.
- ISA101b-OPC-01-19 A Phase II Study of cemiplimab, an anti-PD-1 monoclonal antibody, and ISA101b vaccine in patients with recurrent/metastatic HPV16-positive Oropharyngeal Cancer who have experienced disease progression with prior anti-PD-1 therapy
- XRAY-VISION A randomized, double-blind, placebo-controlled, 2-arm Phase III study to assess efficacy and safety of xevinapant and radiotherapy compared to placebo and radiotherapy for demonstrating improvement of disease-free survival in participants with resected squamous cell carcinoma of the head and neck, who are at high risk for relapse and are ineligible for high-dose cisplatin

Phase II, III No profit trials:

- PROSE - HSRL-02-2007 Randomized proteomic based phase II study of standard second-line erlotinib versus standard chemotherapy in patients with inoperable non-small cell lung cancer-
- ITACA Phase III Multicenter Randomized Trial Comparing Adjuvant pharmacogenomic Driven Chemotherapy versus Standard Adjuvant Chemotherapy in Completely resected Stage II-IIIa Non Small Cell Lung Cancer - Principal Investigator
- ACC LUNG Validation of the Alliance Against Cancer lung panel in patients with Non Small Cell Lung Cancer
- SOPRANO Multicenter PR-prospective Observational Study on the use of adjuvant chemotherapy treatment in radically operated non-small cell lung cancer (NSCLC) patients in stage IB-IIIa
- SENECA Multicenter, prospective, open-label study in patients with stage IIIB / IV or relapsed non-small cell lung cancer after failure of first-line chemotherapy that evaluates efficacy and safety of oral BIBF1120 in combination with standard therapy with docetaxel,
- Validation study of a method that allows the isolation of circulating tumor cells in patients with metastatic non-small cell lung cancer (ESTA)- Principal Investigator.
- Review of the Neuregulin / HER cell cascade in invasive lung adenocarcinoma: comparison of diagnostic pathways on biological samples from Italian patients. (THERAPY)
- ACC-ImmunoPortal, an Italian data-repository for the optimization of immunotherapy with ICI: an ambispective observational study. (Immunotherapy study)-
- The role of geriatric assessment in personalizing the treatment choice of the elderly - patients with locally advanced head and neck cancer. (Elderly)
- International registry on thoracic cancer patients with COVID-19 TERAVOLT (Thoracic cancer international COVID-19 collaboration) (Studio Teravolt)
- National Project on Vaccines, COVID and frail patients. A multicentric observational prospective study to assess the immune response of COVID-19 vaccination in frail patients (VAX4FRIAL)

- OncoHome: home management of the oncology patient in oral therapy: containment of the Covid-19 pandemic and prevention of new outbreaks. (OncoHome)
- MITO 25.1 A randomized, molecular driven phase II trial of Carboplatin-Paclitaxel-Bevacizumab vs Carboplatin-Paclitaxel-Bevacizumab-Rucaparib vs Carboplatin-Paclitaxel-Rucaparib, selected according to HRD status, in patients with advanced (stage III B-C-IV) ovarian, primary peritoneal and Fallopian tube cancer preceded by a phase I dose escalation study on Rucaparib-Bevacizumab combination.
- A-Brave Adjuvant Treatment For High-Risk Triple Negative Breast Cancer Patients With the Anti-Pd-L1 Antibody Avelumab: A Phase Iii Randomized Trial
- BIG 4-11 A randomized multicenter, double-blind, placebo-controlled comparison of chemotherapy plus trastuzumab plus placebo versus chemotherapy plus trastuzumab plus pertuzumab as adjuvant therapy in patients with operable HER2-positive primary breast cancer
- GIM 3 (no-profit) A phase III study comparing anastrozole, letrozole and exemestane, upfront (for 5 years) or sequentially (for 3 years after 2 years of tamoxifen), as adjuvant treatment of postmenopausal patients with endocrine-responsive breast cancer.
- GIM 10 (no-profit) A phase III study comparing the concurrent versus the sequential administration of chemotherapy and aromatase inhibitors, as adjuvant treatment of postmenopausal patients with endocrineresponsive early breast cancer.
- GIM 16 (no-profit) Fulvestrant and Everolimus plus Exemestane in metastatic breast cancer
- AIR AIOCC Italian Registry on Head and Neck Carcinomas
- POINT Pembrolizumab and olaparib in recurrent/metastatic, platinum resistant nasopharyngeal cancer
- PRIME H&N Induction and maintenance treatment with PARP inhibitor and immunotherapy in HPV-negative Head and Neck Squamous Cell Carcinoma (HNSCC)
- REALKEY Prospective cohort study in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck treated with first-line systemic treatment. Identification of therapeutic choices in the real-life setting and repository of radiologic images and histologic specimens.

Grants or Funding obtained for the design and conduct of clinical studies

Fund management on behalf of research groups:

- ❖ 2016 ACC (Alleanza contro il cancro) Research Working Group project 1
Period: 2017
Sum: 200 833.45 euros
Role: Principal Investigator
- ❖ 2017 ACC (Alleanza contro il cancro) Research Working Group project 1
Period: 2018
Sum: 200,000.00 euros
Role: Principal Investigator
- ❖ 2018 ACC (Alleanza contro il cancro) Research Working Group 1 project
Period: 2019
Sum: 270,000.00 euros

Role: Principal Investigator

- ❖ 2019 ESTA Protocol Menarini Lung
Period: 2019-2021
Sum: industrial agreement
Role: Principal Investigator
- ❖ 2019 ACC (Alleanza contro il cancro) Research Working Group 1 project
Period: 2020
Sum: 88 500.00 euros
Role: Principal Investigator
- ❖ Bank of Italy call 2019
Period: 2020
Sum: 135,000.00 euros
- ❖ 2020 ACC (Alleanza contro il cancro) Research Working Group 1
Period: 2020 – 2021
Sum: 285,000.00 euros
Role: Principal Investigator
- ❖ 2021 ACC (Alleanza contro il cancro) Research Working Group project 1
Period: 2021-2022
Sum: 500,000.00 euros
Role: Principal Investigator

Independently managed grants:

- ❖ Grant: Ministry, Targeted Research
The silent revolution: integrating novel clinical and biomolecular prognostic / predictive factors for risk stratification in NON-SMALL CELL LUNG CANCER.
Period: 2009-2010
Sum: 55,000.00 euros
Role: Sub-investigator
- ❖ Grant: Biodesix Spa Project: SR 07/10 + 10/8 + bis
Randomized Proteomic Stratified Phase III Study of Second Line Erlotinib versus Chemotherapy in Patients with Inoperable Non-Small Cell Lung Cancer- Tissue Analysis.
Period: 2008-2013
Sum: 189,600.00
Role: Principal Investigator
- ❖ Grant: Italian Association for Cancer Research (AIRC)
Mass Spectrometry to Predict Outcome for NSCLC Patients Treated with EGFR TKIs
Period: 2007-2010
Sum: 100,000.00 euros
Role: Principal Investigator

- ❖ Grant: Biodesix Spa
PROSE study
Period: 2010
Sum: \$ 52,998.00
Role: Principal Investigator
- ❖ Grant: Biodesix Spa
Late Follow-up PROSE study
Period: 2013
Sum: 134 250.00 euros
Role: Principal Investigator
- ❖ Grant: Biodesix Spa
PROSE study
Period: 2010-2014
Sum: 105,000.00 euros
Role: Principal Investigator
- ❖ Grant Multisponsor
Oncohome project
Period 2021
Sum: 75,000.00
Role: Principal investigator

Total Euro 2,391,181.45

OTHER RELEVANT ACTIVITIES

- ❖ 2020- **Scientific reviewer** for The Lancet Journal.
- ❖ 2020- **Review Editor** of the Editorial Board for Frontiers in Oncology Journal
- ❖ 2019- **Vice president and founder of Association Arte di Curare** (Arts of Cure) Patients and Care Givers Association to support Oncological Patients and Doctors in the process of cure and communication by involvement of artist and professionals of communication
- ❖ 2017- **Editorial Board Member**, Pulmonology and Respiratory Medicine (I am AIOM, ASCO, IASCLC and ESMO member)
- ❖ Since 2017- **Editorial Panel Member** for the following scientific journals: EC Pulmonology and Respiratory Medicine and Current Pharmaceutical Biotechnology.
- ❖ 2015- **Scientific Director** of www.tumorealpolmone.it web site dedicated to patients and care givers
- ❖ 2015- **Founder and Scientific Director** of Ultraspecialisti srl - Social innovation Startup operating in telemedicine health services
- ❖ 2015- **Founder of LUCE** Italian Lung Cancer Network www.lucenetwork.it to promote National clinical trial network
- ❖ 2010-2013- **Member of the Scientific Committee of San Raffaele Scientific Retreat** - IRCCS, University Hospital San Raffaele
- ❖ 2009- **Member of the San Raffaele Hospital Intellectual Property Committee** for the evaluation of patent term extension for international validity

- ❖ 2004-2006- **Member of ESMO committee** for “Moses Project”: Analysis of EU oncological competences in different countries (within clinical hospitals/ research institutes / universities)
- ❖ 2001-2006- **General Secretary of Flims Alumni Club** (since 2001) and then Vice President-Flims Alumni Club (2003-2006). The Flims Alumni Club (FAC), an Advisory Member of ECCO - the European Cancer Organization, is a non-profit organization that was established in 2001 with the objective to foster the research in good clinical practice at European level
- ❖ 2001- **Founding Member of Ars Vivendi Patients Association** for psychological support of cancer patients in Umbria
- ❖ 1999- **Founding Member** of Umbrian branch of Italian Society of Psycho-oncology
- ❖ 1998-2001- **Coordinator**: Palliative care home assistance for cancer patients-Umbria

GRANTS, PATENTS AND AWARDS

2017, 2018, 2019- **Italian Alliance Against Cancer grant for WG Lung**

2010-2013- **Ministry of Health Award**. The silent revolution: integrating novel clinical and bio-molecular prognostic/predictive factors for risk stratification in NON-SMALL-CELL LUNG CANCER - “Participating Unit” (02/08/2010-02/08/2013)

2007-2009- **AIRC grant** for: “Mass Spectrometry to Predict Outcome in NSCLC Patients”

2008-2013 **Grant** for SR 07/10 Study Randomized Proteomic Stratified Phase III Study of Second Line Erlotinib versus Chemotherapy in Patients with Inoperable Non-Small Cell Lung Cancer

2008- **AIOM AWARD** for the best poster presented at 10th AIOM National Congress, Verona, 2008: Phase II trial of NGR-hTNF, a novel vascular targeting agent (VTA), in malignant pleural mesothelioma (MMP)

2006- **Patent**: Royalty return from the licensing contract with Biodesix Technologies, INC, for the identification and setup of the method and system for selection of patients eligible for targeted therapy with mass spectrometry. United States Patent # 7,736,905; Roder, et. al.; Method and system for determining whether a drug will be effective on a patient with a disease; issued June 15, 2010.

1995- **Winner of bi-annual national scholarship sponsored by the AUCC** (Associazione Umbra per la Lotta Contro il Cancro) – Umbrian Association for action against cancer

MEMBER OF SOCIETIES

AIOM, ESMO, ASCO, IALSC, EORTC.

PERSONAL SKILLS

<i>Languages</i>	ITALIAN/CROATIAN: Native ENGLISH: Proficient GERMAN, SLOVENIAN: <i>very elementary proficiency</i>
<i>Computer Skills</i>	Windows, Word, Excel, Outlook Express, Eudora, Internet Explorer, and Netscape
<i>Soft Skills</i>	Painting, Theatre, Running, Sailing
<i>Driving License</i>	B

LIST of PUBLICATIONS **Scopus Author ID: 6603449479**

1. F. Roila, V. De Angelis, E. Corgna, **V. Gregorc**. Advances in supportive care. *Ann. Oncol.* 9 (3):52-54. 1998.
2. S. Darwish, **V. Gregorc**. Inibitori dell'angiogenesi: molte aspettative poche dati. Review. *Rivista trimestrale di informazione scientifica: Τεχνη Update in Oncology and Hematology* Vol 4, n° 1. 2000: 54-56.
3. L. Cagini, M. Monacelli, G. Giustozzi, L. Moggi, G. Bellezza, A. Sidoni, E. Bucciarelli, S. Darwish, V. Ludovini, L. Pistola, **V. Gregorc**, M. Tonato. Biological Prognostic Factors For Early Stage Completely Resected Non-Small Cell Lung Cancer. *J Surg Oncol.* 2000 May;74(1):53-60.
4. **V. Gregorc**, V. Ludovini, L. Pistola, S. Darwish, I. Floriani, G. Bellezza, A. Sidoni, A. Cavaliere, M. Scheibel, V. De Angelis, E. Bucciarelli, M. Tonato. Relevance Of P53, Bcl-2 And Rb Expression On Resistance To Cisplatin-Based Chemotherapy In Advanced Non Small Cell Lung Cancer (NSCLC) *Lung Cancer* 39 (2003) 41-48
5. GL Ceresoli, P. Zucchinelli, M. Ponzoni, **V. Gregorc**, K. Bencardino, CT Paties. Mediastinal follicular dendritic cell sarcoma. *Haematologica* 2003;88(2):ECR04.
6. F. Cappuzzo, **V. Gregorc**, E. Rossi, A. Cancellieri, E. Magrini, CT Paties, GL Ceresoli, L. Lombardo, S. Bartolini, C. Calandri, M. de Rosa, E. Villa, L. Crinò: Gefitinib In Pretreated Non Small-Cell Lung Cancer (NSCLC): Analysis of Efficacy and Correlation With HER2 And Epidermal Growth factor Receptor Expression in Locally Advanced or metastatic NSCLC. *J Clin Oncol* 21 (14): 2658-2663, 2003.
7. F. Cappuzzo, G. Selvaggi, **V. Gregorc**, F. Mazzoni, M. Betti, MR Migliorino, S. Novello, A. Maestri, F. De Marinis, S. Darwish, V. De Angelis, F. Nelli, S. Bartolini, G. V. Scagliotti, M. Tonato, L. Crinò: Gemcitabine-Cisplatin As Induction Chemotherapy for Patients with Unresectable Stage IIIA-Bulky N2 and IIIB Non-small Cell Lung Carcinoma, An Italian Lung Cancer Project Observational Study, *Cancer* 2003, 1;98(1):128-34.

8. **Gregorc V**, Darwish S, Ludovini V, Pistola L, De Angelis V, Mihaylova Z, Bellezza G, Sidoni A, Cavaliere A, Bucciarelli E, Massaro G, Tonato M. The clinical relevance of Bcl-2, Rb and p53 expression in advanced non-small cell lung cancer. *Lung Cancer*. 2003 Dec; 42(3): 275-81.
9. Cappuzzo F, Bartolini S, Ceresoli GL, Tamberi S, Spreafico A, Lombardo L, **Gregorc V**, Toschi L, Calandri C, Villa E, Crino L. Efficacy and tolerability of gefitinib in pretreated elderly patients with advanced non-small-cell lung cancer (NSCLC). *Br J Cancer*. 2004 Jan 12; 90(1): 82-6.
10. Ceresoli GL, Cappuzzo F, **Gregorc V**, Bartolini S, Crino L, Villa E. Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial. *Ann Oncol*. 2004 Jul;15(7):1042-1047.
11. Cappuzzo F, Magrini E, Ceresoli GL, Bartolini S, Rossi E, Ludovini V, **Gregorc V**, Ligorio C, Cancellieri A, Damiani S, Spreafico A, Paties CT, Lombardo L, Calandri C, Bellezza G, Tonato M, Crino L. Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer. *J Natl Cancer Inst*. 2004 Aug 4;96(15):1133-41
12. Ludovini V, **Gregorc V**, Pisola L, Mihaylova Z, Floriani I, Darwish S, Stracci F, Toffanetti FR, Ferraldeschi M, Di Carlo L, Ragusa M, Daddi G, Tonato M. Vascular endothelial growth factor, p53, Rb, Bcl-2 expression and response to chemotherapy in advanced non-small cell lung cancer. *Lung Cancer*. 2004 Oct;46(1):77-85.
13. Ceresoli GL, **Gregorc V**, Cordio S, Bencardino KB, Schipani S, Cozzarini C, Bordonaro R, Villa E. Phase II study of weekly paclitaxel as second-line therapy in patients with advanced non-small cell lung cancer. *Lung Cancer*. 2004 May;44(2):231-9.
14. **Gregorc V**, Ceresoli GL, Floriani I, Spreafico A, Bencardino KB, Ludovini V, Pistola L, Mihaylova Z, Tofanetti FR, Ferraldeschi M, Torri V, Cappuzzo F, Crino L, Tonato M, Villa E. Effects of gefitinib on serum epidermal growth factor receptor and HER2 in patients with advanced non-small cell lung cancer. *Clin Cancer Res*. 2004 Sep 15;10(18 Pt 1):6006-12.
15. Cappuzzo F, Varella-Garcia M, Shigematsu H, Domenichini I, Bartolini S, Ceresoli GL, Rossi E, Ludovini V, **Gregorc V**, Toschi L, Franklin WA, Crino L, Gazdar AF, Bunn PA Jr, Hirsch FR. Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients. *J Clin Oncol*. 2005 Aug 1;23(22):5007-18.
16. Cappuzzo F, Hirsch FR, Rossi E, Bartolini S, Ceresoli GL, Bemis L, Haney J, Witta S, Danenberg K, Domenichini I, Ludovini V, Magrini E, **Gregorc V**, Doglioni C, Sidoni A, Tonato M, Franklin WA, Crino L, Bunn PA Jr, Varella-Garcia M. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. *J Natl Cancer Inst*. 2005 May 4;97(9):643-55.
17. Messa C, Ceresoli GL, Rizzo G, Artioli D, Cattaneo M, Castellone P, **Gregorc V**, Picchio M, Landoni C, Fazio F. Feasibility of [(18)F]FDG-PET and coregistered CT on clinical target volume definition of advanced non-small cell lung cancer. *Q J Nucl Med Mol Imaging*. 2005 Sep;49(3):259-66.

18. Cusatis G, **Gregorc V**, Li J, Spreafico A, Ingersoll RG, Verweij J, Ludovini V, Villa E, Hidalgo M, Sparreboom A, Baker SD. Pharmacogenetics of ABCG2 and adverse reactions to gefitinib. *J Natl Cancer Inst.* 2006 Dec 6;98(23):1739-42.
19. Gridelli C, Kaukel E, **Gregorc V**, Migliorino MR, Muller TR, Manegold C, Favaretto A, Martoni A, Caffo O, Schmittel A, Rossi A, Russo F, Peterson P, Munoz M, Reck M. Single-agent pemetrexed or sequential pemetrexed/gemcitabine as front-line treatment of advanced non-small cell lung cancer in elderly patients or patients ineligible for platinum-based chemotherapy: a multicenter, randomized, phase II trial. *J Thorac Oncol.* 2007 Mar;2(3):221-9.
20. Ceresoli GL, Cattaneo GM, Castellone P, Rizzos G, Landoni C, **Gregorc V**, Calandrino R, Villa E, Messa C, Santoro A, Fazio F. Role of computed tomography and [18F] fluorodeoxyglucose positron emission tomography image fusion in conformal radiotherapy of non-small cell lung cancer: a comparison with standard techniques with and without elective nodal irradiation. *Tumori.* 2007 Jan-Feb;93(1):88-96.
21. **Gregorc V**, Spreafico A, Floriani I, Colombo B, Ludovini V, Pistola L, Bellezza G, Viganò MG, Villa E, Corti A. Prognostic value of circulating chromogranin A and soluble tumor necrosis factor receptors in advanced nonsmall cell lung cancer. *Cancer.* 2007 Aug 15;110(4):845-53.
22. Taguchi F, Solomon B, **Gregorc V**, Roder H, Gray R, Kasahara K, Nishio M, Brahmer J, Spreafico A, Ludovini V, Massion PP, Dziadziuszko R, Schiller J, Grigorieva J, Tsy-pin M, Hunsucker SW, Caprioli R, Duncan MW, Hirsch FR, Bunn PA Jr, Carbone DP. Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study. *J Natl Cancer Inst.* 2007 Jun 6;99(11):838-46.
23. Giovannini M, **Gregorc V**, Viganò MG, Spreafico A, Ghio D, Dell'Oca I, Bolognesi A, Villa E. Endothelial growth factor receptor inhibition after radiotherapy. *J Thorac Oncol.* 2007 Jul;2(7):662.
24. Ludovini V, Pistola L, **Gregorc V**, Floriani I, Rulli E, Piattoni S, Di Carlo L, Semeraro A, Darwish S, Tofanetti FR, Stocchi L, Mihaylova Z, Bellezza G, Del Sordo R, Daddi G, Crinò L, Tonato M. Plasma DNA, microsatellite alterations, and p53 tumor mutations are associated with disease-free survival in radically resected non-small cell lung cancer patients: a study of the Perugia multidisciplinary team for thoracic oncology. *J Thorac Oncol.* 2008 Apr;3(4):365-73.
25. Ludovini V, Pistola L, **Gregorc V**, Floriani I, Rulli E, Di Carlo L, Semeraro A, Daddi G, Darwish S, Stocchi L, Tofanetti FR, Bellezza G, Sidoni A, Tognellini R, Crinò L, Tonato M. Biological markers and DNA flow cytometric analysis in radically resected patients with non-small cell lung cancer. A study of the Perugia Multidisciplinary Team for Thoracic Tumors. *Tumori.* 2008 May-Jun;94(3):398-405.
26. Giovannini M, Belli C, Villa E, **Gregorc V**. Estrogen receptor (ER) and epidermal growth factor receptor (EGFR) as targets for dual lung cancer therapy: not just a case? *J Thorac Oncol.* 2008 Jun;3(6):684-5.

27. **Gregorc V**, Hidalgo M, Spreafico A, Cusatis G, Ludovini V, Ingersoll RG, Marsh S, Steinberg SM, Viganò MG, Ghio D, Villa E, Sparreboom A, Baker SD. Germline polymorphisms in EGFR and survival in patients with lung cancer receiving gefitinib. *Clin Pharmacol Ther.* 2008 Mar;83(3):477-84.
28. Giovannini M, **Gregorc V**, Belli C, Roca E, Lazzari C, Viganò MG, Serafico A, Villa E. Clinical Significance of Skin Toxicity due to EGFR-Targeted Therapies. *J Oncol.* 2009;2009:849051. Epub 2009 Jun 22.
29. **Gregorc V**, Santoro A, Bennicelli E, Punt CJ, Citterio G, Timmer-Bonte JN, Caligaris Cappio F, Lambiase A, Bordignon C, van Herpen CM. Phase Ib study of NGR-hTNF, a selective vascular targeting agent, administered at low doses in combination with doxorubicin to patients with advanced solid tumours. *Br J Cancer.* 2009 Jul 21;101(2):219-24..
30. **Gregorc V**, Citterio G, Vitali G, Spreafico A, Scifo P, Borri A, Donadoni G, Rossoni G, Corti A, Caligaris-Cappio F, Del Maschio A, Esposito A, De Cobelli F, Dell'Acqua F, Troysi A, Bruzzi P, Lambiase A, Bordignon C. Defining the optimal biological dose of NGR-hTNF, a selective vascular targeting agent, in advanced solid tumours. *Eur J Cancer.* 2010 Jan;46(1):198-206.
31. **Gregorc V**, Zucali PA, Santoro A, Ceresoli GL, Citterio G, De Pas TM, Zilembo N, De Vincenzo F, Simonelli M, Rossoni G, Spreafico A, Viganò MG, Fontana F, De Braud FG, Bajetta E, Caligaris -Cappio F, Bruzzi P, Lambiase A, Bordignon C. Phase II study of NGR-hTNF, a selective vascular targeting agent, in previously treated patients with malignant pleural mesothelioma. *Journal of Clinical Oncology* 2010 May 20;28(15):2604-11.
32. Spitaleri G, Delmonte A, Toffalorio F, De Pas TM, **Gregorc V**. Safety of concomitant administration of seasonal and/or H1N1 flu vaccination in patients receiving erlotinib for advanced non-small cell lung cancer. *J Thorac Oncol.* 2010 May;5(5):752-4.
33. **Gregorc V**, de Braud F, De Pas TM, Scalamogna R, Citterio G, Milani A, Boselli S, Catania C, Donadoni G, Rossoni G, Ghio D, Spitaleri G, Ammannati C, Colombi S, Caligaris-Cappio F, Lambiase A, Bordignon C. Phase I Study of NGR-hTNF, a Selective Vascular Targeting Agent, in Combination with Cisplatin in Refractory Solid Tumours. *Clin Cancer Res.* 2011
34. **Gregorc V**, Melloni G, Bandiera A, Carretta A, Ciriaco P, Viganò M, Franzin A, Bolognesi A, Picozzi P, Zannini P. Combined treatment of non-small cell lung cancer with synchronous brain metastases: a single center experience. *J Cardiovasc Surg.* 2011 Aug;52(4):613-9.
35. Sprowl JA, **Gregorc V**, Lazzari C, Mathijssen RH, Loos WJ, Sparreboom A. Associations Between ABCC2 Polymorphisms and Cisplatin Disposition and Efficacy. *Clin Pharmacol Ther.* 2012 Jun;91(6):1022-6..
36. Lazzari C, Spreafico A, Bachi A, Roder H, Floriani I, Garavaglia D, Cattaneo A, Grigorieva J, Viganò MG, Sorlini C, Ghio D, Tsy-pin M, Bulotta A, Bergamaschi L, **Gregorc V**. Changes in plasma mass-spectral profile in course of treatment of non-small cell lung cancer patients with epidermal growth factor receptor tyrosine kinase inhibitors. *J Thorac Oncol.* 2012 Jan;7(1):40-8.
37. Milan E, Lazzari C, Anand S, Floriani I, Torri V, Sorlini C, **Gregorc V**, Bachi A. SAA1 is over-expressed in plasma of non small cell lung cancer patients with poor outcome after

- treatment with epidermal growth factor receptor tyrosine-kinase inhibitors. *J Proteomics*. 2012 Jul 4.
38. Bearz A, Talamini R, Rossoni G, Santo A, de Pangher V, Fasola G, Rosetti F, Favaretto A, **Gregorc V**, Berretta M, Santarossa S, Berto E, Tirelli U. Re-challenge with pemetrexed in advanced mesothelioma: a multi-institutional experience. *BMC Res Notes*. 2012 Sep 3;5(1):482.
 39. Tartarone A, Lazzari C, Lerosé R, Conteduca V, Improta G, Zupa A, Bulotta A, Aieta M, **Gregorc V**. Mechanisms of resistance to EGFR tyrosine kinase inhibitors gefitinib/erlotinib and to ALK inhibitor crizotinib. *Lung Cancer*. 2013 Jun 25
 40. Corti A, Curnis F, Rossoni G, Marcucci F, **Gregorc V**. Peptide-Mediated Targeting of Cytokines to Tumor Vasculature: The NGR-hTNF Example. *BioDrugs*. 2013 Jun 7.
 41. Tartarone A, Lerosé R, Lazzari C, **Gregorc V**, Aieta M. Which tyrosine kinase inhibitor should be recommended as initial treatment for non-small cell lung cancer patients with EGFR mutations? *Med Oncol*. 2014 Aug;31(8): 78
 42. **Gregorc V**, Novello S, Lazzari C, Barni S, Aieta M, Mencoboni M, Grossi F, Pas TD, de Marinis F, Bearz A, Floriani I, Torri V, Bulotta A, Cattaneo A, Grigorieva J, Tsy-pin M, Roder J, Doglioni C, Levra MG, Petrelli F, Foti S, Viganò M, Bachi A, Roder H. Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trial. *Lancet Oncol*. 2014 Jun;15(7):713-21.
 43. Deutsch E, Cohen-Jonathan Moyal E, **Gregorc V**, Zucali PA, Menard J, Soria JC, Kloos I, Hsu J, Luan Y, Liu E, Ve-zan R, Graef T, Rivera S. A phase 1 dose-escalation study of the oral histone deacetylase inhibitor abexinostat in combination with standard hypofractionated radiotherapy in advanced solid tumors. *Oncotarget*. 2016 Dec 24.
 44. Peters S, Stahel RA, Dafni U, Ponce Aix S, Massutí B, Gautschi O, Coate L, López Martín A, van Heemst R, Berghmans T, Meldgaard P, Cobo Dols M, Garde Noguera J, Curioni-Fontecedro A, Rauch D, Mark MT, Cuffe S, Biesma B, van Henten AM, Juan Vidal Ó, Palmero Sanchez R, Villa Guzmán JC, Collado Martin R, Peralta S, Insa A, Summers Y, Láng I, Horgan A, Ciardiello F, de Hosson S, Pieterman R, Groen HJ, van den Berg PM, Zielinski CC, Chittazhathu Kurian Kuruvilla Y, Gasca-Ruchti A, Kassapian M, Novello S, Torri V, Tsourti Z, **Gregorc V**, Smit EF; EMPHASIS-lung Collaborative Group. Randomized Phase III Trial of Erlotinib versus Docetaxel in Patients with Advanced Squamous Cell Non-Small Cell Lung Cancer Failing First-Line Platinum-Based Doublet Chemotherapy Stratified by VeriStrat Good versus VeriStrat Poor. The European Thoracic Oncology Platform (ETOP) EMPHASIS-lung Trial. *J Thorac Oncol*. 2017 Apr;12(4):752-762
 45. Lazzari C, Bulotta A, Ducceschi M, Viganò MG, Brioschi E, Corti F, Gianni L, **Gregorc V**. Historical Evolution of Second-Line Therapy in Non-Small Cell Lung Cancer. *Front Med (Lausanne)*. 2017 Jan 23;4:4.
 46. Cortinovis D, **Gregorc V**, Migliorino MR, Abate MI, Manzo A, Malapelle U, Morabito A; Italian Lung Cancer Working Group. New perspectives in the second-line treatment of non squamous NSCLC patients: Results from a large Italian Lung Cancer Working Group. *Crit Rev Oncol Hematol*. 2017 Jan;109:35-41.

47. Lazzari C, Karachaliou N, **Gregorc V**, Bulotta A, Gonzalez-Cao M, Verlicchi A, Altavilla G, Rosell R, Santarpia M. Second-line therapy of squamous non-small cell lung cancer: an evolving landscape. *Expert Rev Respir Med*. 2017 Jun;11(6):469-479.
48. Gobbini E, Galetta D, Tiseo M, Graziano P, Rossi A, Bria E, Di Maio M, Rossi G, **Gregorc V**, Riccardi F, Scotti V, Ceribelli A, Buffoni L, Delmonte A, Franchina T, Migliorino MR, Cortinovis D, Pisconti S, Bordi P, Catino A, Maiello E, Arizio F, Novello S; other Co-Authors. Molecular profiling in Italian patients with advanced non-small-cell lung cancer: An observational prospective study. *Lung Cancer*. 2017 Sep;111:30-37. doi: 10.1016/j.lungcan.2017.06.009. Epub 2017 Jun 16.
49. Metro G, Passaro A, Lo Russo G, Bonanno L, Giusti R, **Gregorc V**, Capelletto E, Martelli O, Cecere FL, Giannarelli D, Luciani A, Bearz A, Tuzi A, Scotti V, Tonini G, Galetta D, Carta A, Soto Parra H, Rebonato A, Morabito A, Chiari R. Ceritinib compassionate use for patients with crizotinib-refractory, anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer. *Future Oncol*. 2017 Nov 14. doi: 10.2217/fon-2017-0441.
50. Oltolini C, Ripa M, Andolina A, Brioschi E, Cilla M, Petrella G, **Gregorc V**, Castiglioni B, Tassan Din C, Scarpellini P.; Invasive Pulmonary Aspergillosis Complicated by Carbapenem-Resistant *Pseudomonas aeruginosa* Infection During Pembrolizumab Immunotherapy for Metastatic Lung Adenocarcinoma: Case Report and Review of the Literature. *Mycopathologia*. 2018 Aug 13. doi: 10.1007/s11046-018-0291-4. [Epub ahead of print]
51. **Gregorc V**, Cavina R, Novello S, Grossi F, Lazzari C, Capelletto E, Genova C, Salini G, Lambiase A, Santoro A.; NGR-hTNF and Doxorubicin as Second-Line Treatment of Patients with Small Cell Lung Cancer. *Oncologist*. 2018 Aug 3. pii: theoncologist.2018-0292. doi: 10.1634/theoncologist.2018-0292. [Epub ahead of print]
52. Petrelli F, Lazzari C, Ardito R, Borgonovo K, Bulotta A, Conti B, Cabiddu M, Capitanio JF, Brighenti M, Ghilardi M, Gianni L, Barni S, **Gregorc V**.; Efficacy of ALK inhibitors on NSCLC brain metastases: A systematic review and pooled analysis of 21 studies. *PLoS One*. 2018 Jul 27;13(7):e0201425. doi: 10.1371/journal.pone.0201425. eCollection 2018.
53. **Gregorc V**, Lazzari C, Karachaliou N, Rosell R, Santarpia M.; Osimertinib in untreated epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer. *Transl Lung Cancer Res*. 2018 Apr;7(Suppl 2):S165-S170. doi: 10.21037/tlcr.2018.03.19. No abstract available.
54. **Gregorc V**, Gaafar RM, Favaretto A, Grossi F, Jassem J, Polychronis A, Bidoli P, Tiseo M, Shah R, Taylor P, Novello S, Muzio A, Bearz A, Greillier L, Fontana F, Salini G, Lambiase A, O'Brien M; NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trial. *Lancet Oncol*. 2018 Jun;19(6):799-811. doi: 10.1016/S1470-2045(18)30193-1. Epub 2018 May 9.
55. Lazzari C, Karachaliou N, Bulotta A, Viganó M, Mirabile A, Brioschi E, Santarpia M, Gianni L, Rosell R, **Gregorc V**.; Combination of immunotherapy with chemotherapy and radiotherapy in lung cancer: is this the beginning of the end for cancer? *Ther Adv Med*

- Oncol. 2018 Apr 6;10:1758835918762094. doi: 10.1177/1758835918762094. eCollection 2018. Review.
56. Oltolini C, Ripa M, Andolina A, Brioschi E, Cilla M, Petrella G, **Gregorc V**, Castiglioni B, Tassan Din C, Scarpellini P. Invasive Pulmonary Aspergillosis Complicated by Carbapenem-Resistant *Pseudomonas aeruginosa* Infection During Pembrolizumab Immunotherapy for Metastatic Lung Adenocarcinoma: Case Report and Review of the Literature. *Mycopathologia*. 2018 Aug 13. doi: 10.1007/s11046-018-0291-4.
 57. **Gregorc V**, Cavina R, Novello S, Grossi F, Lazzari C, Capelletto E, Genova C, Salini G, Lambiase A, Santoro A. NGR-hTNF and Doxorubicin as Second-Line Treatment of Patients with Small Cell Lung Cancer. *Oncologist*. 2018 Oct;23(10):1133-e112. doi: 10.1634/theoncologist.2018-0292. Epub 2018 Aug
 58. Petrelli F, Lazzari C, Ardito R, Borgonovo K, Bulotta A, Conti B, Cabiddu M, Capitanio JF, Brighenti M, Ghilardi M, Gianni L, Barni S, **Gregorc V**. Efficacy of ALK inhibitors on NSCLC brain metastases: A systematic review and pooled analysis of 21 studies. *PLoS One*. 2018 Jul 27;13(7):e0201425. doi: 10.1371/journal.pone.0201425. eCollection 2018.
 59. Garassino MC, Kawaguchi T, **Gregorc V**, Rulli E, Ando M, Marsoni S, Isa SI, Novello S, Farina G, Barni S, Torri V, Cinquini M. Chemotherapy versus erlotinib as second-line treatment in patients with advanced non-small cell lung cancer and wild-type epidermal growth factor receptor: an individual patient data (IPD) analysis. *ESMO Open*. 2018 Nov 1;3(6):e000327. doi: 10.1136/esmoopen-2018-000327. eCollection 2018.
 60. Lazzari C, **Gregorc V**, Bulotta A, Dottore A, Altavilla G, Santarpia M. Temozolomide in combination with either veliparib or placebo in patients with relapsed-sensitive or refractory small-cell lung cancer. *Transl Lung Cancer Res*. 2018 Dec;7(Suppl 4):S329-S333
 61. Lazzari C, **Gregorc V**, Cangi MG, Giovannetti E, Bulotta A, Santarpia M. Combined exosomal RNA and circulating tumor DNA for epidermal growth factor mutation detection in non-small cell lung cancer. *J Thorac Dis*. 2018 Nov;10(Suppl 33):S4023-S4027. doi: 10.21037/jtd.2018.10.17.
 62. Francaviglia I, Magliacane G, Lazzari C, Grassini G, Brunetto E, Dal Cin E, Girlando S, Medicina D, Smart CE, Bulotta A, **Gregorc V**, Pecciarini L, Doglioni C, Cangi MG. Identification and monitoring of somatic mutations in circulating cell-free tumor DNA in lung cancer patients. *Lung Cancer*. 2019 Aug;134:225-232. doi: 10.1016/j.lungcan.2019.06.010.
 63. Capelletto E, Migliorino MR, Morabito A, Chiari R, Grossi F, Tiseo M, Costanzo FD, Delmonte A, Romano G, Galetta D, Scotti V, **Gregorc V**, Pisconti S, Ceresoli GL, Conte AD, Ciuffreda L, Colantonio I, Bria E, Ricciardi S, Manzo A, Metro G, Morelli AM, Critelli R, Pacchiana MV, Stura I, Migliaretti G, Novello S. Final results of the SENECA (SEcond line NintEdanib in non-small cell lung CAncer) trial. *Lung Cancer*. 2019 Aug;134:210-217. doi: 10.1016/j.lungcan.2019.06.028.
 64. Mirabile A, Brioschi E, Ducceschi M, Piva S, Lazzari C, Bulotta A, Viganò MG, Petrella G, Gianni L, **Gregorc V**. PD-1 Inhibitors-Related Neurological Toxicities in Patients with Non-Small-Cell Lung Cancer: A Literature Review. *Cancers (Basel)*. 2019 Mar 1;11(3). pii: E296. doi: 10.3390/cancers11030296.

65. Lazzari C, **Gregorc V**, Bulotta A, Dottore A, Altavilla G, Santarpia M. Temozolomide in combination with either veliparib or placebo in patients with relapsed-sensitive or refractory small-cell lung cancer. *Transl Lung Cancer Res.* 2018 Dec;7(Suppl 4):S329-S333. doi: 10.21037/tlcr.2018.12.02.
66. Capelletto E, Migliorino MR, Morabito A, Chiari R, Grossi F, Tiseo M, Di Costanzo F, Delmonte A, Romano G, Galetta D, Scotti V, **Gregorc V**, Pisconti S, Ceresoli GL, Del Conte A, Ciuffreda L, Colantonio I, Bria E, Ricciardi S, Manzo A, Metro G, Morelli AM, Critelli R, Pacchiana MV, Stura I, Migliaretti G, Novello S. Final results of the SENECA (SEcond line NintEdanib in non-small cell lung CAncer) trial. *Lung Cancer* 2019 Aug;134:210-217. doi: 10.1016/j.lungcan.2019.06.028.
67. Ilaria Francaviglia, Gilda Magliacane, Chiara Lazzari, Greta Grassini, Emanuela Brunetto, Elena Dal Cin, Salvatore Girlando, Daniela Medicina, Chanel Elisha Smart, Alessandra Bulotta, **Vanesa Gregorc**, Lorenza Pecciarini, Claudio Doglioni, Maria Giulia Cangi Identification and monitoring of somatic mutations in circulating cell-free tumor DNA in lung cancer patients.. *Lung Cancer.* 2019 Aug;134:225-232. doi: 10.1016/j.lungcan.2019.06.010.
68. Martina Baiardo Redaelli, Alberto Zangrillo, **Vanesa Gregorc**, Fabio Ciceri, Lorenzo Dagna, Yamume Tshomba, Paolo Navalesi, Giovanni Landoni How to obtain severe hypoglycemia without causing brain or cardiac damage. *Med Hypotheses.* 2019 Sep;130:109276. doi: 10.1016/j.mehy.2019.109276.
69. Chiara Lazzari, **Vanesa Gregorc**, Mariacarmela Santarpia Impact of clinical features of epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) patients on osimertinib efficacy. *J Thorac Dis.* 2019 Nov;11(11):4400-4403. doi: 10.21037/jtd.2019.10.67.
70. Nobuyuki Yamamoto, Hidetoshi Hayashi, David Planchard, Teresa Morán, **Vanesa Gregorc**, Jonathan Dowell, Hiroshi Sakai, Kiyotaka Yoh, Makoto Nishio, Alexis B Cortot, Karim A Benhadji, Nital Soni, Jinhong Huang, Lukas Makris, Susana Cedres A randomized, phase 2 study of deoxyuridine triphosphatase inhibitor, TAS-114, in combination with S-1 versus S-1 alone in patients with advanced non-small-cell lung cancer.. *Invest New Drugs.* 2020 Oct;38(5):1588-1597. doi: 10.1007/s10637-020-00930-5.
71. Andrea Pontara, Giovanni Paolino, **Vanesa Gregorc**, Santo Raffaele Mercuri, Alessandra Bulotta, Pietro Bearzi, Claudio Doglioni, Nathalie Rizzo Immunohistochemical Evaluation and Clinicopathological Correlation of Mer and Axl Tyrosine Kinase TAM Receptors in Cutaneous Melanoma. *Dermatol Pract Concept.* 2020 Apr 3;10(2):e2020029. doi: 10.5826/dpc.1002a29. eCollection 2020.
72. Aurora Mirabile, Licia Rivoltini, Elena Daveri, Claudio Vernieri, Roberto Mele, Luca Porcu, Chiara Lazzari, Alessandra Bulotta, Maria Grazia Viganò, Stefano Cascinu, **Vanesa Gregorc** Metabolism and Immune Modulation in Patients with Solid Tumors: Systematic Review of Preclinical and Clinical Evidence.. *Cancers (Basel).* 2020 May 4;12(5):1153. doi: 10.3390/cancers12051153.
73. Angelo Carretta, Alessandro Bandiera, Piergiorgio Muriana, Stefano Viscardi, Paola Ciriaco, Ana Maria Samanes Gajate, Gianluigi Arrigoni, Chiara Lazzari, **Vanesa Gregorc**,

- Giampiero Negri. Prognostic role of positron emission tomography and computed tomography parameters in stage I lung adenocarcinoma. *Radiol Oncol.* 2020 May 28;54(3):278-284. doi: 10.2478/raon-2020-0034.
74. Marina Chiara Garassino, Jennifer G Whisenant, Li-Ching Huang, Annalisa Trama, Valter Torri, Francesco Agustoni, Javier Baena, Giuseppe Banna, Rossana Berardi, Anna Cecilia Bettini, Emilio Bria 11, Matteo Brighenti, Jacques Cadranel, Alessandro De Toma, Claudio Chini, Alessio Cortellini, Enriqueta Felip, Giovanna Finocchiaro, Pilar Garrido, Carlo Genova, Raffaele Giusti, **Vanesa Gregorc**, Francesco Grossi, Federica Grosso, Salvatore Intagliata, Nicla La Verde, Stephen V Liu, Julien Mazieres, Edoardo Mercadante, Olivier Michielin, Gabriele Minuti, Denis Moro-Sibilot, Giulia Pasello, Antonio Passaro, Vieri Scotti, Piergiorgio Solli, Elisa Stroppa, Marcello Tiseo, Giuseppe Viscardi, Luca Voltolini, Yi-Long Wu, Silvia Zai, Vera Pancaldi, Anne-Marie Dingemans, Jan Van Meerbeeck, Fabrice Barlesi, Heather Wakelee, Solange Peters, Leora Horn. COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study *Lancet Oncol.* 2020 Jul;21(7):914-922. doi: 10.1016/S1470-2045(20)30314-4.
 75. Chiara Lazzari, **Vanesa Gregorc**, Niki Karachaliou, Rafael Rosell, Mariacarmela Santarpia. Mechanisms of resistance to osimertinib. *J Thorac Dis.* 2020 May;12(5):2851-2858. doi: 10.21037/jtd.2019.08.30.
 76. Danilo Rocco, **Vanesa Gregorc**, Luigi Della Gravara, Chiara Lazzari, Giovanni Palazzolo, Cesare Gridelli. New immunotherapeutic drugs in advanced non-small cell lung cancer (NSCLC): from preclinical to phase I clinical trials. *Expert Opin Investig Drugs.* 2020 Sep;29(9):1005-1023. doi: 10.1080/13543784.2020.1793956.
 77. Giovanni Paolino, Nathalie Rizzo, Riccardo Pampena, Pietro Bearzi, Alessandra Bulotta, **Vanesa Gregorc**, Pina Brianti, Elisa Moliterni, Santo Raffaele Mercuri. Spontaneous Regression of Primary Melanoma and Multiple Melanocytic Nevi in a Patient With Metastatic Melanoma. *Dermatol Pract Concept.* 2020 Jun 29;10(3):e2020052. doi: 10.5826/dpc.1003a52. eCollection 2020 Jul.
 78. Giovanni Paolino, Pietro Bearzi, Riccardo Pampena, Caterina Longo, Pasquale Frascione, Nathalie Rizzo, Margherita Raucci, Anna Carbone, Carmen Cantisani, Francesco Ricci, Dario Didona, Francesca Frattini, Alessandra Bulotta, **Vanesa Gregorc**, Santo R Mercuri. Clinicopathological and dermoscopic features of amelanotic and hypomelanotic melanoma: a retrospective multicentric study.. *Int J Dermatol.* 2020 Jul 29. doi: 10.1111/ijd.15064.
 79. Alex Friedlaender, Alfredo Addeo, Alessandro Russo, **Vanesa Gregorc**, Diego Cortinovis, Christian D Rolfo. Targeted Therapies in Early Stage NSCLC: Hype or Hope?. *Int J Mol Sci.* 2020 Aug 31;21(17):6329. doi: 10.3390/ijms21176329.
 80. Aurora Mirabile, Matteo Biafora, Leone Giordano, Gianluigi Arrigoni, Maria Giulia Cangì, Italo Dell'Oca, Francesca Lira Luce, Davide Di Santo, Andrea Galli, Michele Tulli, Renata Mellone, Davide Valsecchi, **Vanesa Gregorc**, Mario Bussi. Uncommon Site of Metastasis and Prolonged Survival in Patients with Anaplastic Thyroid Carcinoma: A Systematic Review of the Literature *Cancers (Basel).* 2020 Sep 10;12(9):2585. doi: 10.3390/cancers12092585.
 81. Lazzari C, Bulotta A, Cangì MG, Bucci G, Pecciarini L, Bonfiglio S, Lorusso V, Ippati S, Arrigoni G, Grassini G, Doglioni C, **Gregorc V**. Next Generation Sequencing in Non-Small

- Cell Lung Cancer: Pitfalls and Opportunities. *Diagnostics (Basel)*. 2020 Dec 15;10(12):1092. doi: 10.3390/diagnostics10121092.
82. **Gregorc V**, Mazzarella L, Lazzari C, Graziano P, Vigneri P, Genova C, Toschi L, Ciliberto G, Bonanno L, Delmonte A, Bucci G, Rossi A, Motta G, Coco S, Marinello A, Buglioni S, Cangi MG, Di Micco C, Bandiera A, Bonfiglio S, Pecciarini L, Guida A, Ceol A, Frige' G, De Maria R, Pelicci PG. Prospective Validation of the Italian Alliance Against Cancer Lung Panel in Patients With Advanced Non-Small-Cell Lung Cancer. *Clin Lung Cancer*. 2021 Feb 25:S1525-7304(20)30350-8. doi: 10.1016/j.clcc.2020.12.007.
83. Lazzari C, Mirabile A, Bulotta A, Viganó MG, Ogliari FR, Ippati S, DellOca I, Santarpia M, Lorusso V, Reck M, **Gregorc V**. History of Extensive Disease Small Cell Lung Cancer Treatment: Time to Raise the Bar? A Review of the Literature. *Cancers (Basel)*. 2021 Feb 27;13(5):998. doi: 10.3390/cancers13050998.
84. **Gregorc V**, Lazzari C, Mandalá M, Ippati S, Bulotta A, Cangi MG, Khater A, Viganò MG, Mirabile A, Pecciarini L, Ogliari FR, Arrigoni G, Grassini G, Veronesi G, Doglioni C. Intratumoral Cellular Heterogeneity: Implications for Drug Resistance in Patients with Non-Small Cell Lung Cancer. *Cancers (Basel)*. 2021 Apr 22;13(9):2023. doi: 10.3390/cancers13092023.
85. Gagliardi F, De Domenico P, Snider S, Roncelli F, Pompeo E, Barzaghi LR, Bulotta A, **Gregorc V**, Lazzari C, Cascinu S, Finocchiaro G, Mortini P. Role of stereotactic radiosurgery for the treatment of brain metastasis in the era of immunotherapy: A systematic review on current evidences and predicting factors. *Crit Rev Oncol Hematol*. 2021 Jul 27;165:103431. doi: 10.1016/j.critrevonc.2021.10343 .PMID: 34324961 Review.
86. Novellis P, Cominesi SR, Rossetti F, Mondoni M, **Gregorc V**, Veronesi G. Lung cancer screening: who pays? Who receives? The European perspectives. *Transl Lung Cancer Res*. 2021 May;10(5):2395-2406. doi: 10.21037/tlcr-20-677.PMID: 34164287 . Review.
87. Paolino G, Cicinelli MV, Brianti P, Prezioso C, Bulotta A, Rizzo N, Bandello F, Lugini L, Federici C, **Gregorc V**, Modorati GM, Mercuri SR. Eruptive cherry angiomas and uveal melanoma: beyond a simple association. *Clin Exp Dermatol*. 2021 Jul;46(5):946-948. doi: 10.1111/ced.14609.
88. Campochiaro C, Trignani G, Tomelleri A, Cascinu S, Dagna L; COVID-19 Vaccine Study Group. Collaborators Giacomo De Luca, Giulio Cavalli, Luca Moroni, Silvia Sartorelli, Emanuel Della-Torre, Elena Baldissera, Nicola Boffini, Giulia Di Colo, Adriana Cariddi, **Vanesa Gregorc**, Giampaolo Bianchini, Michele Reni, Monica Ronzoni Potential acceptance of COVID-19 vaccine in rheumatological patients: a monocentric comparative survey. *Ann Rheum Dis*. 2021 Jan 28:annrheumdis-2020-219811. doi: 10.1136/annrheumdis-2020-219811.
89. Campochiaro C, Farina N, Tomelleri A, Ferrara R, Lazzari C, De Luca G, Bulotta A, Signorelli D, Palmisano A, Vignale D, Peretto G, Sala S, Esposito A, Garassino M, **Gregorc V**, Dagna L. Tocilizumab for the treatment of immune-related adverse events: a systematic literature review and a multicentre case series. *Eur J Intern Med*. 2021 Nov;93:87-94. doi: 10.1016/j.ejim.2021.07.016. Epub 2021 Aug 12. PMID: 34391591

90. Massafra M, Passalacqua MI, Gebbia V, Macrì P, Lazzari C, **Gregorc V**, Buda C, Altavilla G, Santarpia M. Immunotherapeutic Advances for NSCLC. *Biologics*. 2021 Oct 8;15:399-417. doi: 10.2147/BTT.S295406. eCollection 2021.
91. Pujol JL, Vansteenkiste J, Paz-Ares Rodríguez L, Gregorc V, Mazieres J, Awad M, Jänne PA, Chisamore M, Hossain AM, Chen Y, Beck JT Abemaciclib in Combination With Pembrolizumab for Stage IV KRAS-Mutant or Squamous NSCLC: A Phase 1b Study. *JTO Clin Res Rep*. 2021 Sep 25;2(11):100234. doi: 10.1016/j.jtocrr.2021.100234. eCollection 2021 Nov. PMID: 34746886
92. Novellis P, Monaco F, Landoni G, Rossetti F, Carretta A, **Gregorc V**, Zangrillo A, Veronesi G. Venoarterial Extracorporeal Membrane Oxygenation Support in Lung Cancer Resection. *Ann Thorac Surg*. 2022 Mar;113(3):e191-e193. doi: 10.1016/j.athoracsur.2021.05.040. Epub 2021 Jun 8. PMID: 34111383
93. Novello S, Torri V, Grohe C, Kurz S, Serke M, Wehler T, Meyer A, Ladage D, Geissler M, Colantonio I, Cauchi C, Stoelben E, Ceribelli A, Kropf-Sanchen C, Valmadre G, Borra G, Schena M, Morabito A, Santo A, **Gregorc V**, Chiari R, Reck M, Schmid-Bindert G, Folprecht G, Griesinger F, Follador A, Pedrazzoli P, Bearz A, Caffo O, Dickgreber NJ, Irtelli L, Wiest G, Monica V, Porcu L, Manegold C, Scagliotti GV. International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmaco-genomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIa non-small-cell lung cancer. *Ann Oncol*. 2022 Jan;33(1):57-66. doi: 10.1016/j.annonc.2021.09.017. PMID: 34624497 Clinical Trial.
94. Lazzari C, Bulotta A, Damiano G, Mirabile A, Viganó M, Veronesi G, **Gregorc V**. Angiogenesis inhibition in lung cancer: emerging novel strategies. *Curr Opin Oncol*. 2022 Jan 1;34(1):107-114. doi: 10.1097/CCO.0000000000000807. PMID: 34812193 Review.
95. Tabbò F, Muscarella LA, Gobbin E, Trombetta D, Castellana S, Rigutto A, Galetta D, Maiello E, Martelli O, Tiseo M, Scotti V, Ghilardi L, **Gregorc V**, Sergi C, Pilotto S, Del Conte A, Cappuzzo F, Cortinovis D, Osman G, Bareggi C, Di Maio M, Rossi A, Rossi G, Bria E, Volante M, Scagliotti GV, Graziano P, Novello S, Righi L. Detection of ALK fusion variants by RNA-based NGS and clinical outcome correlation in NSCLC patients treated with ALK-TKI sequences. *Eur J Cancer*. 2022 Oct;174:200-211. doi: 10.1016/j.ejca.2022.07.026. Epub 2022 Aug 28. PMID: 36044814
96. Campochiaro C, Farina N, Tomelleri A, Ferrara R, Viola S, Lazzari C, De Luca G, Raggi D, Bulotta A, Matucci-Cerinic M, Necchi A, Garassino M, **Gregorc V**, Dagna L. Autoantibody positivity predicts severity of rheumatic immune-related adverse events to immune-checkpoint inhibitors. *Eur J Intern Med*. 2022 Sep; 103:95-99. doi: 10.1016/j.ejim.2022.07.005. Epub 2022 Jul 9. PMID: 35821192
97. Ciliberto G, Canfora M, Terrenato I, Agnoletto C, Agustoni F, Amoroso L, Baldassarre G, Curigliano G, Delmonte A, De Luca A, Fiorentino M, **Gregorc V**, Ibrahim T, Lazzari C, Mastronuzzi A, Pronzato P, Santoro A, Scambia G, Tommasi S, Vingiani A, Giacomini P, De Maria R. Bridging therapeutic opportunities: a survey by the Italian molecular tumor board workgroup of Alliance Against Cancer. *J Exp Clin Cancer Res*. 2022 Oct 17;41(1):305. doi: 10.1186/s13046-022-02512-0. PMID: 36245005

98. Cascetta P, Marinello A, Lazzari C, **Gregorc V**, Planchard D, Bianco R, Normanno N, Morabito A. KRAS in NSCLC: State of the Art and Future Perspectives. *Cancers (Basel)*. 2022 Nov 4;14(21):5430. doi: 10.3390/cancers14215430. PMID: 36358848 Free PMC article. Review.
99. Lazzari C, Pecciarini L, Doglioni C, Pedica F, Gajate AMS, Bulotta A, **Gregorc V**, Cangi MG. Case report: EML4::NTRK3 gene fusion in a patient with metastatic lung adenocarcinoma successfully treated with entrectinib. *Front Oncol*. 2022 Nov 7;12:1038774. doi: 10.3389/fonc.2022.1038774. eCollection 2022. PMID: 36419889
100. Lazzari C, Yacoub MR, Campochiaro C, Bulotta A, Palumbo D, Ogliari FR, Dagna L, Marchesi S, Ponzoni M, **Gregorc V**. Case report: Successful use of mepolizumab for immune checkpoint inhibitors-induced hypereosinophilic syndrome in two patients with solid malignancies. *Front Oncol*. 2023 Jan 26;13:1079034. doi: 10.3389/fonc.2023.1079034. eCollection 2023. PMID: 36776300
101. Valsecchi D, Porcu L, Khater A, Battista RA, Giordano L, Cascinu S, Assanelli A, Lazzari C, **Gregorc V**, Mirabile A. Emergency Department Visits among Cancer Patients during SARS-CoV-2 Pandemic. *Cancers (Basel)*. 2023 Feb 15;15(4):1240. doi: 10.3390/cancers15041240. PMID: 36831581
102. Lazzari C, Spagnolo CC, Ciappina G, Di Pietro M, Squeri A, Passalacqua MI, Marchesi S, Gregorc V, Santarpia M. Immunotherapy in Early-Stage Non-Small Cell Lung Cancer (NSCLC): Current Evidence and Perspectives. *Curr Oncol*. 2023 Mar 27;30(4):36843696. doi:10.3390/curroncol30040280. PMID: 37185393 Free PMC article. Review.
103. Pecciarini L, Brunetto E, Grassini G, De Pascali V, Ogliari FR, Talarico A, Marra G, Magliacane G, Redegalli M, Arrigoni G, Lazzari C, **Gregorc V**, Bulotta A, Doglioni C, Cangi MG. Gene Fusion Detection in NSCLC Routine Clinical Practice: Targeted-NGS or FISH? *Cells*. 2023 Apr 11;12(8):1135. doi: 10.3390/cells12081135. PMID: 37190044 Free PMC article.
104. Wakelee H, Liberman M, Kato T, Tsuboi M, Lee SH, Gao S, Chen KN, Doms C, Majem M, Eigendorff E, Martinengo GL, Bylicki O, Rodríguez-Abreu D, Chaft JE, Novello S, Yang J, Keller SM, Samkari A, Spicer JD; **KEYNOTE-671 Investigators**. Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer. *N Engl J Med*. 2023 Aug 10;389(6):491-503. doi: 10.1056/NEJMoa2302983. Epub 2023 Jun 3. PMID: 37272513 Clinical Trial.
105. Park KU, Cha C, Pozzi G, Kang YJ, **Gregorc V**, Sapino A, Gazzetta G, Marrazzo E, Toesca A. Robot-assisted Nipple Sparing Mastectomy: Recent Advancements and Ongoing Controversies. *Curr Breast Cancer Rep*. 2023;15(2):127-134. doi: 10.1007/s12609-023-00487-1. Epub 2023 Apr 27. PMID: 37293274 Free PMC article. Review.
106. Lupia T, Crisà E, Gaviraghi A, Rizzello B, Di Vincenzo A, Carnevale-Schianca F, Caravelli D, Fizzotti M, Tolomeo F, Vitolo U, De Benedetto I, Shbaklo N, Cerutti A, Fenu P, **Gregorc V**, Corcione S, Ghisetti V, De Rosa FG. Strongyloides spp. and Cytomegalovirus Co-Infection in Patient Affected by Non-Hodgkin Lymphoma. *Trop Med Infect Dis*. 2023 Jun 20;8(6):331. doi: 10.3390/tropicalmed8060331. PMID: 37368749

107. Rizzo A, Cantale O, Mogavero A, Garetto L, Racca M, Venesio T, Anpalakhan S, Novello S, **Gregorc V**, Banna GL. Assessing the role of colonic and other anatomical sites uptake by [18 F]FDG-PET/CT and immune-inflammatory peripheral blood indexes in patients with advanced non-small cell lung cancer treated with first-line immune checkpoint inhibitors. *Thorac Cancer*. 2023 Aug;14(24):2473-2483. doi: 10.1111/1759-7714.15032. Epub 2023 Jul 13. PMID: 37442801
108. Lupia T, Crisà E, Gaviraghi A, Rizzello B, Di Vincenzo A, Carnevale-Schianca F, Caravelli D, Fizzotti M, Tolomeo F, Vitolo U, De Benedetto I, Shbaklo N, Cerutti A, Fenu P, **Gregorc V**, Corcione S, Ghisetti V, De Rosa FG. Overlapping Infection by *Strongyloides* spp. And Cytomegalovirus in the Immunocompromised Host: A Comprehensive Review of the Literature. *Trop Med Infect Dis*. 2023 Jul 10;8(7):358. doi: 10.3390/tropicalmed8070358. PMID: 37505654
109. Trono P, Tocci A, Palermo B, Di Carlo A, D'Ambrosio L, D'Andrea D, Di Modugno F, De Nicola F, Goeman F, Corleone G, Warren S, Paolini F, Panetta M, Sperduti I, Baldari S, Visca P, Carpano S, Cappuzzo F, Russo V, Tripodo C, Zucali P, **Gregorc V**, Marchesi F, Nistico P. hMENA isoforms regulate cancer intrinsic type I IFN signaling and extrinsic mechanisms of resistance to immune checkpoint blockade in NSCLC. *J Immunother Cancer*. 2023 Aug;11(8):e006913. doi: 10.1136/jitc-2023-006913. PMID: 37612043
110. Wakelee H, Liberman M, Kato T, Tsuboi M, Lee SH, Gao S, Chen KN, Doooms C, Majem M, Eigendorff E, Martinengo GL, Bylicki O, Rodríguez-Abreu D, Chaft JE, Novello S, Yang J, Keller SM, Samkari A, Spicer JD, KEYNOTE-671 Investigators.; Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer *N Engl J Med*. 2023 Aug 10;389(6):491-503. doi:10.1056/NEJMoa2302983. Epub 2023 Jun 3. PMID: 37272513 Clinical Trial.
111. Longo BM, Venuti F, Gaviraghi A, Lupia T, Ranzani FA, Pepe A, Ponzetta L, Vita D, Allice T, **Gregorc V**, Frascione PMM, De Rosa FG, Calcagno A, Bonora S. Sequential or Combination Treatments as Rescue Therapies in Immunocompromised Patients with Persistent SARS-CoV-2 Infection in the Omicron Era: A Case Series. *Antibiotics (Basel)*. 2023 Sep 19;12(9):1460. doi: 10.3390/antibiotics12091460. PMID: 37760757
112. Lupia T, Carnevale-Schianca F, Vita D, Busca A, Caravelli D, Crisà E, **Gregorc V**, Curtioni A, Cerutti A, Shbaklo N, Corcione S, De Rosa FG. *Stenotrophomonas maltophilia* Infections in Haematological Malignancies and Hematopoietic Stem Cell Transplantation: A Case Series including Cefiderocol-Based Regimens. *Medicina (Kaunas)*. 2024 Jan 3;60(1):88. doi: 10.3390/medicina60010088. PMID: 38256349
113. Lupia T, Crisà E, Sangiorgio V, Bosio R, Stroffolini G, Staffilano E, **Gregorc V**, Corcione S, De Rosa FG. Presumptive pulmonary toxocariasis in a patient affected by acute myeloid leukemia and Hodgkin lymphoma: case report and review of the literature in immunocompromised hosts. *Infez Med*. 2024 Mar 1;32(1):103-112. doi: 10.53854/liim-3201-14. eCollection 2024. PMID: 38456027

.....
 I authorize the processing of my personal data according to art. 13 of Legislative Decree 196/2003 and art. 13 of GDPR 679/16.

April 2024

Vanesa Gregorc, MD

A handwritten signature in blue ink, appearing to read "Vanesa Gregorc". The signature is fluid and cursive, with a long horizontal stroke at the end.